CN116768877A - Isr抑制剂及其制备方法和应用 - Google Patents
Isr抑制剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN116768877A CN116768877A CN202310592077.1A CN202310592077A CN116768877A CN 116768877 A CN116768877 A CN 116768877A CN 202310592077 A CN202310592077 A CN 202310592077A CN 116768877 A CN116768877 A CN 116768877A
- Authority
- CN
- China
- Prior art keywords
- synthesis
- yield
- nmr
- carboxamide
- white solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000003112 inhibitor Substances 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 229940002612 prodrug Drugs 0.000 claims abstract description 12
- 239000000651 prodrug Substances 0.000 claims abstract description 12
- 239000012453 solvate Substances 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 210000004885 white matter Anatomy 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000014616 translation Effects 0.000 abstract description 11
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 abstract description 7
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 238000001243 protein synthesis Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000638 stimulation Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 description 231
- 238000003786 synthesis reaction Methods 0.000 description 230
- 239000007787 solid Substances 0.000 description 143
- 238000005481 NMR spectroscopy Methods 0.000 description 142
- -1 tert-butyl trans- (4- (5-chlorobenzofuran-2-carboxamido) cyclohexyl) carbamate Chemical compound 0.000 description 121
- 238000000034 method Methods 0.000 description 97
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 37
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- JDTASEYRNDUTJV-UHFFFAOYSA-N 5-chloro-1-benzofuran-2-carboxamide Chemical compound ClC1=CC=C2OC(C(=O)N)=CC2=C1 JDTASEYRNDUTJV-UHFFFAOYSA-N 0.000 description 26
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Substances ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- SNBPPCREDOZGPM-UHFFFAOYSA-N 6-chloroquinoline-2-carboxamide Chemical compound C1=C(Cl)C=CC2=NC(C(=O)N)=CC=C21 SNBPPCREDOZGPM-UHFFFAOYSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- JETRXAHRPACNMA-UHFFFAOYSA-N 5-chloro-1-benzofuran-2-carboxylic acid Chemical compound ClC1=CC=C2OC(C(=O)O)=CC2=C1 JETRXAHRPACNMA-UHFFFAOYSA-N 0.000 description 5
- HCPODGJMFLAPEZ-UHFFFAOYSA-N 6-bromoquinoline-2-carboxamide Chemical compound C1=C(Br)C=CC2=NC(C(=O)N)=CC=C21 HCPODGJMFLAPEZ-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- NRVQSRYGSQYPAG-UHFFFAOYSA-N 3-(4-chlorophenyl)-1,2,4-oxadiazole-5-carboxylic acid Chemical compound O1C(C(=O)O)=NC(C=2C=CC(Cl)=CC=2)=N1 NRVQSRYGSQYPAG-UHFFFAOYSA-N 0.000 description 4
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HJGMCDHQPXTGAV-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-[[2-(4-chlorophenoxy)acetyl]amino]cyclohexyl]acetamide Chemical compound C1=CC(Cl)=CC=C1OCC(=O)NC1CCC(NC(=O)COC=2C=CC(Cl)=CC=2)CC1 HJGMCDHQPXTGAV-UHFFFAOYSA-N 0.000 description 3
- HZAARXYRNUBDNS-UHFFFAOYSA-N 2-(trifluoromethoxy)ethanol Chemical compound OCCOC(F)(F)F HZAARXYRNUBDNS-UHFFFAOYSA-N 0.000 description 3
- PKBGHORNUFQAAW-UHFFFAOYSA-N 4-chlorobenzohydrazide Chemical compound NNC(=O)C1=CC=C(Cl)C=C1 PKBGHORNUFQAAW-UHFFFAOYSA-N 0.000 description 3
- ASSVYHKYJOKDQY-UHFFFAOYSA-N 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-carboxylic acid Chemical compound O1C(C(=O)O)=NN=C1C1=CC=C(Cl)C=C1 ASSVYHKYJOKDQY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PLUGBNQLEAERCO-UHFFFAOYSA-N OC(=O)COC1CC(C1)OC(F)(F)F Chemical compound OC(=O)COC1CC(C1)OC(F)(F)F PLUGBNQLEAERCO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- AJKIAERFLWQLAM-UHFFFAOYSA-N 2-(chloromethyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole Chemical compound O1C(CCl)=NN=C1C1=CC=C(Cl)C=C1 AJKIAERFLWQLAM-UHFFFAOYSA-N 0.000 description 2
- SNTDMGMZOXNPPJ-UHFFFAOYSA-N 4-chloro-n'-(2-chloroacetyl)benzohydrazide Chemical compound ClCC(=O)NNC(=O)C1=CC=C(Cl)C=C1 SNTDMGMZOXNPPJ-UHFFFAOYSA-N 0.000 description 2
- GJNGXPDXRVXSEH-UHFFFAOYSA-N 4-chlorobenzonitrile Chemical compound ClC1=CC=C(C#N)C=C1 GJNGXPDXRVXSEH-UHFFFAOYSA-N 0.000 description 2
- WWBORYCPYRIYDX-UHFFFAOYSA-N 5-chloro-1-benzofuran-2-carbohydrazide Chemical compound ClC1=CC=C2OC(C(=O)NN)=CC2=C1 WWBORYCPYRIYDX-UHFFFAOYSA-N 0.000 description 2
- PWHHLZAKLPOCGN-UHFFFAOYSA-N 5-chloro-1h-indole-2-carbohydrazide Chemical compound ClC1=CC=C2NC(C(=O)NN)=CC2=C1 PWHHLZAKLPOCGN-UHFFFAOYSA-N 0.000 description 2
- BXWLFCFYDFRSPE-UHFFFAOYSA-N 6-bromoquinoline-2-carbonitrile Chemical compound N1=C(C#N)C=CC2=CC(Br)=CC=C21 BXWLFCFYDFRSPE-UHFFFAOYSA-N 0.000 description 2
- DKTGQKFNZHZSQH-UHFFFAOYSA-N 6-bromoquinoline-3-carboxamide Chemical compound C1=CC(Br)=CC2=CC(C(=O)N)=CN=C21 DKTGQKFNZHZSQH-UHFFFAOYSA-N 0.000 description 2
- MDISQESZDBPYRY-UHFFFAOYSA-N 6-chloroquinoline-2-carbaldehyde Chemical compound N1=C(C=O)C=CC2=CC(Cl)=CC=C21 MDISQESZDBPYRY-UHFFFAOYSA-N 0.000 description 2
- UKMWQYNJAVNCOZ-UHFFFAOYSA-N 6-chloroquinoline-2-carboxylic acid Chemical compound C1=C(Cl)C=CC2=NC(C(=O)O)=CC=C21 UKMWQYNJAVNCOZ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- WZQLZRKONBKLPB-UHFFFAOYSA-N N-(4-aminopiperidin-1-yl)-5-chloro-1-benzofuran-2-carboxamide Chemical compound NC1CCN(CC1)NC(=O)C1=CC2=C(O1)C=CC(Cl)=C2 WZQLZRKONBKLPB-UHFFFAOYSA-N 0.000 description 2
- WYLALTWJIGGONV-HAQNSBGRSA-N N[C@H]1CC[C@@H](CC1)NC(=O)C1=CC2=CC(Cl)=CC=C2O1 Chemical compound N[C@H]1CC[C@@H](CC1)NC(=O)C1=CC2=CC(Cl)=CC=C2O1 WYLALTWJIGGONV-HAQNSBGRSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- XNZBUAFOVHWZNQ-UHFFFAOYSA-N benzyl 3-hydroxycyclobutane-1-carboxylate Chemical compound C1C(O)CC1C(=O)OCC1=CC=CC=C1 XNZBUAFOVHWZNQ-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- HZJHKOBSCAWAOC-UHFFFAOYSA-N ethyl 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-carboxylate Chemical compound O1C(C(=O)OCC)=NN=C1C1=CC=C(Cl)C=C1 HZJHKOBSCAWAOC-UHFFFAOYSA-N 0.000 description 2
- KTBFFSXNFOOSEH-UHFFFAOYSA-N ethyl 5-chloro-1-benzofuran-2-carboxylate Chemical compound ClC1=CC=C2OC(C(=O)OCC)=CC2=C1 KTBFFSXNFOOSEH-UHFFFAOYSA-N 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 208000017445 musculoskeletal system disease Diseases 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- GEHBIWVQKQLYNB-UHFFFAOYSA-N tert-butyl 2-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1N GEHBIWVQKQLYNB-UHFFFAOYSA-N 0.000 description 2
- KUYMVWXKHQSIAS-UHFFFAOYSA-N tert-butyl 2-chloroacetate Chemical compound CC(C)(C)OC(=O)CCl KUYMVWXKHQSIAS-UHFFFAOYSA-N 0.000 description 2
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 2
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 2
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- JJZRXTXSRJLBRX-UHFFFAOYSA-N 2-(4-bromophenyl)-5-(chloromethyl)-1,3,4-oxadiazole Chemical compound O1C(CCl)=NN=C1C1=CC=C(Br)C=C1 JJZRXTXSRJLBRX-UHFFFAOYSA-N 0.000 description 1
- ZXTSFZRZKFXXRG-UHFFFAOYSA-N 2-(4-chlorophenyl)acetohydrazide Chemical compound NNC(=O)CC1=CC=C(Cl)C=C1 ZXTSFZRZKFXXRG-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZGSDRBWWICYJBU-UHFFFAOYSA-N 3-phenylmethoxycyclobutan-1-ol Chemical compound C1C(O)CC1OCC1=CC=CC=C1 ZGSDRBWWICYJBU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ANJMNKUMSGITKU-UHFFFAOYSA-N 4-bromo-n'-(2-chloroacetyl)benzohydrazide Chemical compound ClCC(=O)NNC(=O)C1=CC=C(Br)C=C1 ANJMNKUMSGITKU-UHFFFAOYSA-N 0.000 description 1
- UYIMBYKIIMYFPS-UHFFFAOYSA-N 4-bromobenzohydrazide Chemical compound NNC(=O)C1=CC=C(Br)C=C1 UYIMBYKIIMYFPS-UHFFFAOYSA-N 0.000 description 1
- BHINITWLUJWRTH-UHFFFAOYSA-N 4-chloro-3-fluorobenzohydrazide Chemical compound NNC(=O)c1ccc(Cl)c(F)c1 BHINITWLUJWRTH-UHFFFAOYSA-N 0.000 description 1
- OWQPSMYXFCDDBP-UHFFFAOYSA-N 4-chloro-N'-(2-chloroacetyl)-3-fluorobenzohydrazide Chemical compound ClC1=C(C=C(C(=O)NNC(CCl)=O)C=C1)F OWQPSMYXFCDDBP-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 1
- GZILZCCGDNKAAV-UHFFFAOYSA-N 5-chloro-1h-indole-2-carboxamide Chemical compound ClC1=CC=C2NC(C(=O)N)=CC2=C1 GZILZCCGDNKAAV-UHFFFAOYSA-N 0.000 description 1
- FUGKCSRLAQKUHG-UHFFFAOYSA-N 5-chloro-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Cl)C=C1C=O FUGKCSRLAQKUHG-UHFFFAOYSA-N 0.000 description 1
- UQGCFISFRKCLOL-UHFFFAOYSA-N 6-bromoquinoline-2-carboxylic acid Chemical compound C1=C(Br)C=CC2=NC(C(=O)O)=CC=C21 UQGCFISFRKCLOL-UHFFFAOYSA-N 0.000 description 1
- OCCIBGIEIBQGAJ-UHFFFAOYSA-N 6-chloro-2-methylquinoline Chemical compound C1=C(Cl)C=CC2=NC(C)=CC=C21 OCCIBGIEIBQGAJ-UHFFFAOYSA-N 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- YMBDEWMFHJHGGB-UHFFFAOYSA-N C1CN(CCC1CN)NC(=O)C2=CC3=C(O2)C=CC(=C3)Cl Chemical compound C1CN(CCC1CN)NC(=O)C2=CC3=C(O2)C=CC(=C3)Cl YMBDEWMFHJHGGB-UHFFFAOYSA-N 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- GQQIVOOELDMJKR-WKILWMFISA-N ClC=1C=C2C=CC(=NC2=CC=1)C(=O)N[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O Chemical compound ClC=1C=C2C=CC(=NC2=CC=1)C(=O)N[C@@H]1CC[C@H](CC1)NC(OC(C)(C)C)=O GQQIVOOELDMJKR-WKILWMFISA-N 0.000 description 1
- JVKVDAYJYQJLOD-SHTZXODSSA-N ClC=1C=CC2=C(C=C(O2)C(=O)N[C@@H]2CC[C@H](CC2)NC(OC(C)(C)C)=O)C=1 Chemical compound ClC=1C=CC2=C(C=C(O2)C(=O)N[C@@H]2CC[C@H](CC2)NC(OC(C)(C)C)=O)C=1 JVKVDAYJYQJLOD-SHTZXODSSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 1
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 1
- 102100029775 Eukaryotic translation initiation factor 1 Human genes 0.000 description 1
- 101710204612 Eukaryotic translation initiation factor 1 Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 208000000020 MEHMO syndrome Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- VDAZLTUWJYEPLH-JOCQHMNTSA-N N[C@H]1CC[C@@H](CC1)NC(=O)C1=NC2=CC=C(Cl)C=C2C=C1 Chemical compound N[C@H]1CC[C@@H](CC1)NC(=O)C1=NC2=CC=C(Cl)C=C2C=C1 VDAZLTUWJYEPLH-JOCQHMNTSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000027515 Tracheal disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OPGPYIKNRCXNQY-UHFFFAOYSA-N benzyl 3-oxocyclobutane-1-carboxylate Chemical compound C1C(=O)CC1C(=O)OCC1=CC=CC=C1 OPGPYIKNRCXNQY-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- DNTKXLXLDDGVOB-UHFFFAOYSA-N ethyl 3-(4-chlorophenyl)-1,2,4-oxadiazole-5-carboxylate Chemical compound O1C(C(=O)OCC)=NC(C=2C=CC(Cl)=CC=2)=N1 DNTKXLXLDDGVOB-UHFFFAOYSA-N 0.000 description 1
- RWBYCMPOFNRISR-UHFFFAOYSA-N ethyl 4-chlorobenzoate Chemical compound CCOC(=O)C1=CC=C(Cl)C=C1 RWBYCMPOFNRISR-UHFFFAOYSA-N 0.000 description 1
- ZOZDFQUVDQQEMJ-UHFFFAOYSA-N ethyl 5-(4-bromophenyl)-1,3,4-oxadiazole-2-carboxylate Chemical compound O1C(C(=O)OCC)=NN=C1C1=CC=C(Br)C=C1 ZOZDFQUVDQQEMJ-UHFFFAOYSA-N 0.000 description 1
- SYEMJDNMIWKHLJ-UHFFFAOYSA-N ethyl 5-[(4-chlorophenyl)methyl]-1,3,4-oxadiazole-2-carboxylate Chemical compound O1C(C(=O)OCC)=NN=C1CC1=CC=C(Cl)C=C1 SYEMJDNMIWKHLJ-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- FFKGMXGWLOPOAO-UHFFFAOYSA-N methyl 4-aminocyclohexane-1-carboxylate Chemical compound COC(=O)C1CCC(N)CC1 FFKGMXGWLOPOAO-UHFFFAOYSA-N 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BFFZXKGMIFLKSW-UHFFFAOYSA-N tert-butyl N-[1-[(5-chloro-1-benzofuran-2-carbonyl)amino]piperidin-4-yl]carbamate Chemical compound ClC=1C=CC2=C(C=C(O2)C(=O)NN2CCC(CC2)NC(OC(C)(C)C)=O)C=1 BFFZXKGMIFLKSW-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- FEYLUKDSKVSMSZ-UHFFFAOYSA-N tert-butyl n-(4-aminocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(N)CC1 FEYLUKDSKVSMSZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
本发明公开了一类ISR抑制剂及其制备方法和应用,属于生物医药技术领域。本发明的化合物为具有式(I)或式(II)结构的化合物,其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物,
Description
技术领域
本发明属于生物医药技术领域,具体涉及一类具有ISR抑制活性的化合物及其制备方法和应用。
背景技术
整合应激反应(integrated stress response,ISR)是蛋白质稳态失调时诱发的信号中心调控网络,主要以控制蛋白质合成速率来实现,帮助细胞、组织和生物体适应变化的环境并维持健康。ISR的生物学功能是在压力下恢复细胞内稳态,错误折叠蛋白质的积累会激活ISR反应。该途径在翻译起始水平上起作用抑制整体蛋白质合成,同时促进参与细胞恢复的几种蛋白质的翻译。
ISR的激活是许多神经退行性疾病的共同因素。在广泛的脑部疾病中,检测到了ISR的激活,包括阿尔茨海默病、帕金森病、孤独症谱系障碍(Autistic SpectrumDisorder,ASD)、肌萎缩侧索硬化症(ALS)、创伤性脑损伤等。
ISR在其他疾病方面也具有影响作用。ADAR1的突变能够引起免疫疾病(包括Aicardi-Goutières综合征),药理学抑制ISR能够让ADAR突变小鼠中位存活率提高3倍,并使其恢复到正常体重。另一项研究表明,靶向抑制ISR可以调节小胶质细胞M1/M2表型,对小胶质细胞发挥新的抗炎作用,是外科脑损伤后神经炎症的潜在治疗靶点。通过抑制ISR还可以达到减轻肺纤维化、治疗脊髓损伤和缺血性疾病(心肌梗死和中风等)的效果。
ISR信号能够调控细胞内eIF2三元复合物(ternary complex,TC)的浓度。TC是一种异源三聚体,是由真核翻译起始因子eIF2、GTP和带电荷甲硫酰基-起始转运RNA(Met-tRNAi)组成。翻译起始是一个多步骤过程,mRNA-蛋白质复合物(mRNP)招募包含起始因子eIF1、eIF3和eIF5以及结合GTP和起始tRNA的eIF2复合物的多因子复合物(Multifactorcomplex,MFC),促进三元复合物向40S核糖体亚基的传递。MFC最常被eIF4F复合物招募到mRNA中,eIF4F复合物识别并结合到50cap结构,并定位MFC以从50end扫描到AUG起始密码子。一旦识别到AUG,eIF2对GTP的水解使40S核糖体进入翻译起始,并导致60S亚单位的招募和翻译起始的延长阶段。从核糖体释放eIF2–GDP后,GDP被鸟嘌呤核苷酸交换因子(guaninenucleotide-exchange factor,GEF)eIF2B交换为GTP,为下一轮启动准备eIF2复合物。eIF2B的活性由其底物eIF2的磷酸化、核苷酸和辅因子与eIF2B的结合以及eIF2B自身的磷酸化调节。eIF2B激活剂能促进eIF2B十聚体蛋白的形成,逆转ISR的作用,推动翻译起始并且恢复蛋白质的合成。
因此,研究具有ISR抑制活性的新型化合物对于多种疾病的治疗具有重要意义。
发明内容
本发明的目的是提供一类具有ISR抑制活性的化合物,及其制备方法和应用。
为了实现上述目的,本发明采用以下技术方案:
本发明提供具有式(I)或式(II)结构的化合物,其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物,
其中:
A为卤素取代的双芳香杂环;
D选自
L为
W为五元杂环;
n为0、1或2;
m为0或1;
B为卤素取代的苯环、K选自
G选自在一些实施例中,
A选自
W选自B选自
在一些具体实施例中,本发明提供以下化合物,其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物,但不局限于以下化合物范围:
在本发明中,所述药学上可接受的盐包括具有式(I)或式(II)结构的化合物与下列酸形成的酸加成盐:盐酸、氢溴酸、硫酸、硝酸、磷酸、甲酸、乙酸、三氟乙酸、乳酸、草酸、己二酸、戊二酸、丙二酸、马来酸、琥珀酸、富马酸、酒石酸、柠檬酸、棕榈酸、苯甲酸、甲磺酸、对甲苯磺酸、水杨酸、苯基乙酸、杏仁酸,此外还包括无机碱的酸式盐。
本发明还提供式(I)或式(II)所示化合物的制备方法:
方法1:在缩合剂的作用下,化合物(III)和化合物(V)发生缩合反应,制备得到式(I)化合物;
方法2:极性非质子溶剂中,在碳酸铯的作用下,化合物(III)和化合物(V)发生取代反应,制备得到式(I)化合物;
方法3:在缩合剂的作用下,化合物(VI)和化合物(VII)发生缩合反应,制备得到式(II)化合物;
其中,以上A、B、D、L、W、K、G、m、n的定义如前所述。
本发明还提供一种药物组合物,以本发明所述化合物、其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物为活性成分或者主要活性成分,辅以药学上可接受的载体组成。
本发明还提供本发明所述化合物、其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物在制备治疗和/或预防ISR介导的疾病的药物中的应用。
所述疾病为神经退行性疾病、自身免疫性疾病、肌肉骨骼疾病、炎症性疾病、遗传病症。优选地,所述神经退行性疾病选自:脑缺血、脑损伤、癫痫、阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩性侧索硬化、不同类型脊髓小脑共济失调、孤独症谱系障碍、白质消融性疾病、智力障碍综合征、朊病毒疾病、克雅氏病、中风、慢性创伤性脑病变、脊髓损伤、痴呆、额颞叶型痴呆(FTD)、抑郁症或社交行为障碍;优选地,所述自身免疫性疾病选自:全身性红斑狼疮、1型糖尿病、多发性硬化或类风湿性关节炎;优选地,所述肌肉骨骼疾病选自:肌病、肌肉营养不良、肌肉萎缩、肌肉消瘦或肌肉减少症;优选地,所述炎症性疾病选自:关节炎、牛皮癣性关节炎、牛皮癣、幼年型特发性关节炎、哮喘、过敏性哮喘、支气管哮喘、肺结核、慢性气管病症、囊肿性纤维化、丝球体肾炎、膜性肾病、结节病、血管炎、鱼鳞病、移植物排斥反应、间质性膀胱炎、异位性皮炎或炎症性肠病;优选地,所述遗传病症选自:唐氏综合征或MEHMO综合征(智力迟钝、癫痫发作、性腺机能减退、小头畸形和肥胖症)。
本发明提供的化合物,能够与eIF2B有效结合,具有良好的ATF4抑制能力,在ISR刺激时能够较好的恢复蛋白质的合成。所以,本发明的化合物可作为ISR抑制剂并用于治疗各种相关病症。本发明为在临床上筛选和/或制备治疗和/或预防阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩性侧索硬化、衰老、孤独症谱系障碍、白质消融性疾病、痴呆、额颞叶型痴呆(FTD)等神经退行性疾病的药物提供了一种新的选择。
具体实施方式
下面结合具体实施例对本发明作进一步详细说明,但不应理解为对本发明的限制。在不背离本发明精神和实质的情况下,对本发明方法、步骤或条件所作的修改或替换,均属于本发明的范围。实施例中未注明具体条件的实验方法及未说明配方的试剂均为按照本领域常规条件。
实施例1
中间体反-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)氨基甲酸叔丁酯的合成
步骤1:5-氯苯并呋喃-2-甲酸乙酯的合成
将5-氯水杨醛(0.2g,1.28mmol)溶于N,N-二甲基甲酰胺(10mL)中,加入溴乙酸乙酯(0.32g,1.92mmol)和碳酸钾(0.41g,3.19mmol),升温至120℃,反应10h。乙酸乙酯萃取,无水硫酸钠干燥,经减压浓缩,残留物通过硅胶柱层析(石油醚/乙酸乙酯=200/1)纯化得白色固体204mg,产率71.09%。1H NMR(300MHz,DMSO-d6)δ(ppm):7.89(dd,J=2.2,0.6Hz,1H),7.80(dt,J=8.9,0.8Hz,1H),7.73(d,J=0.9Hz,1H),7.56(dd,J=8.9,2.3Hz,1H),4.37(q,J=7.1Hz,2H),1.34(t,J=7.1Hz,3H).
步骤2:5-氯苯并呋喃-2-羧酸的合成
将5-氯苯并呋喃-2-甲酸乙酯(3.15g,14.00mmol)溶于四氢呋喃/乙醇(15mL/10mL)中,加入氢氧化锂(503mg,21.00mmol),室温反应。反应5h。在冰浴条件下,用1mol/L的盐酸调pH至3,过滤,滤饼经水洗涤和少量乙酸乙酯洗涤,干燥,得到白色固体2.29g,产率83.02%。1H NMR(300MHz,DMSO-d6)δ(ppm):13.78(s,1H),7.87(d,J=2.2Hz,1H),7.77(d,J=8.8Hz,1H),7.63(d,J=0.9Hz,1H),7.53(dd,J=8.9,2.2Hz,1H).
步骤3:反-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)氨基甲酸叔丁酯的合成
将5-氯苯并呋喃-2-羧酸(0.60g,3.05mmol)溶于15mL的N,N-二甲基甲酰胺中,依次加入HATU(2.32g,6.10mmol)、N-Boc-反式-1,4-环己二胺(0.65mg,3.05mmol)和DIPEA(1.58g,12.21mmol),室温下搅拌反应。反应3h。加入30mL水,过滤,滤饼用少量二氯甲烷洗涤,干燥,得到白色固体0.948g,产率79.06%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.62(d,J=8.1Hz,1H),7.87(d,J=2.2Hz,1H),7.70(d,J=8.8Hz,1H),7.56 -7.45(m,2H),6.79(d,J=8.0Hz,1H),3.79 -3.63(m,1H),3.20(d,J=10.6Hz,1H),1.81(d,J=11.5Hz,4H),1.48(d,J=12.5Hz,2H),1.38(s,9H),1.33-1.20(m,2H).。
实施例2
中间体反-N-(4-氨基环己基)-5-氯苯并呋喃-2-甲酰胺的合成
将反-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)氨基甲酸叔丁酯(948mg,2.41mmol)溶于二氯甲烷(10mL)中,加入三氟乙酸(1mL),室温条件下反应8h。将反应液减压浓缩,用氨水调pH至10,过滤,滤饼洗涤,干燥,得到淡黄色固体586mg,产率82.95%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.68(d,J=8.0Hz,1H),7.88(d,J=2.7Hz,1H),7.70(d,J=8.8Hz,1H),7.55-7.45(m,2H),3.75(s,1H),2.99(d,J=8.4Hz,1H),2.01-1.85(m,4H),1.42(qd,J=11.4,5.6Hz,4H).。
实施例3
5-(4-氯苯基)-1,3,4-噁二唑-2-甲酸乙酯的合成
步骤1:4-氯苯甲酰肼的合成
将4-氯苯甲酸乙酯(5.00g,27.08mmol)溶于甲醇(50mL)中,加入80%水合肼(6.78g,135.41mmol),升温至80℃回流反应,反应12h。将反应液浓缩,用少量石油醚/乙酸乙酯洗涤,过滤,干燥,得到白色固体4.10g,产率88.65%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.73(s,1H),7.73-7.66(m,2H),7.48-7.41(m,2H),5.87(s,2H).
步骤2:2-(2-(4-氯苯甲酰基)肼基)-2-氧代乙酸乙酯的合成
将4-氯苯甲酰肼(1.96g,11.51mmol)溶于二氯甲烷(15mL)中,加入三乙胺(3.20mL,23.03mmol),接着在冰浴条件下,缓慢滴加草酰氯单乙酯(3.14g,23.03mmol),滴加完毕撤去冰浴,室温反应1h。将反应液减压浓缩,残留物通过硅胶柱层析(石油醚/乙酸乙酯=3/1~1/1)纯化得白色固体2.36g,产率75.74%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.98(s,1H),10.70(s,1H),7.94-7.87(m,2H),7.64-7.58(m,2H),4.22(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).
步骤3:5-(4-氯苯基)-1,3,4-噁二唑-2-甲酸乙酯的合成
将2-(2-(4-氯苯甲酰基)肼基)-2-氧代乙酸乙酯(2.11g,7.80mmol)溶于乙腈(15mL)中,缓慢加入三氯氧磷(3.59g,23.39mmol),升温至85℃封管反应8h。冰浴条件下缓慢加入水,然后用乙酸乙酯萃取,无水硫酸钠干燥,过滤,滤液经减压浓缩,残留物通过硅胶柱层析(石油醚/乙酸乙酯=80/1)纯化得白色固体807mg,产率40.97%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.13-8.05(m,2H),7.77-7.69(m,2H),4.47(q,J=7.1Hz,2H),1.38(t,J=7.1Hz,3H).。
实施例4
反-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-1)的合成
步骤1:5-(4-氯苯基)-1,3,4-噁二唑-2-羧酸的合成
参照实施例1中步骤2所述的方法,得到白色固体149mg,产率57.91%。1H NMR(300MHz,Chloroform-d)δ(ppm):8.50(s,1H),8.08-8.02(m,2H),7.57-7.50(m,2H).
步骤2:反-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-1)的合成
将5-(4-氯苯基)-1,3,4-噁二唑-2-羧酸(59mg,263μmol)溶于乙腈(10mL)中,在冰浴条件下加入草酰氯(25μL,289μmol),再加入1滴N,N-二甲基甲酰胺,反应30min。将反-N-(4-氨基环己基)-5-氯苯并呋喃-2-甲酰胺(77mg,263μmol)溶于二氯甲烷(5mL)中,加入N,N-二异丙基乙胺(102mg,784μmol),随后在冰浴条件下缓慢加入上述反应液,加入完毕后撤去冰浴,室温反应。反应3h。用二氯甲烷萃取,无水硫酸钠干燥,过滤,滤液经减压浓缩,残留物通过硅胶柱层析(二氯甲烷/甲醇=200/1)纯化得到白色固体75mg,产率57.11%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.31(d,J=8.2Hz,1H),8.68(d,J=8.1Hz,1H),8.13(d,J=2.0Hz,1H),8.10(d,J=2.0Hz,1H),7.88(d,J=2.2Hz,1H),7.76-7.68(m,3H),7.54(d,J=1.0Hz,1H),7.49(dd,J=8.8,2.2Hz,1H),3.79(d,J=9.1Hz,2H),1.91(d,J=9.4Hz,4H),1.56(q,J=9.5Hz,4H);MS(ESI)m/z:calculated for C24H20Cl2N4O4[M+H]+:499.09,found:499.0926.。
实施例5
中间体5-(4-氯苄基)-1,3,4-噁二唑-2-甲酸乙酯的合成
步骤1:2-(4-氯苯基)乙酰肼的合成
参照实施例3中步骤1所述的方法,得到白色固体192mg,产率96.00%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.23(s,1H),7.38-7.33(m,2H),7.30-7.25(m,2H),4.22(d,J=3.2Hz,2H),3.35(s,2H).
步骤2:2-(2-(2-(4-氯苯基)乙酰基)肼基)-2-氧代乙酸乙酯的合成
参照实施例3中步骤2所述的方法,得到白色固体1.29g,产率68.30%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.81(s,1H),10.30(s,1H),7.42 -7.36(m,2H),7.35-7.29(m,2H),4.26(q,J=7.1Hz,2H),3.52(s,2H),1.28(t,J=7.1Hz,3H).
步骤3:5-(4-氯苄基)-1,3,4-噁二唑-2-甲酸乙酯的合成
参照实施例3中步骤3所述的方法,得到白色固体821mg,产率68.47%。1H NMR(300MHz,Chloroform-d)δ7.37-7.33(m,2H),7.31-7.27(m,3H),4.51(q,J=7.1Hz,2H),4.28(s,2H),1.45(t,J=7.1Hz,3H).。
实施例6
反-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-5-(4-氯苄基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-2)的合成
步骤1:5-(4-氯苄基)-1,3,4-噁二唑-2-羧酸的合成
参照实施例1中步骤2所述的方法,得到白色固体138mg,产率78.23%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.25(s,1H),7.41-7.35(m,2H),7.35-7.28(m,2H).
步骤2:反-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-5-(4-氯苄基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-2)的合成
参照实施例4中步骤2所述的方法,得到白色固体48mg,产率55.78%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.23(d,J=8.2Hz,1H),8.66(d,J=8.1Hz,1H),7.87(d,J=2.2Hz,1H),7.70(d,J=8.9Hz,1H),7.53(d,J=0.9Hz,1H),7.49(dd,J=8.9,2.2Hz,1H),7.47-7.42(m,2H),7.42-7.35(m,2H),4.39(s,2H),3.75(s,2H),1.86(t,J=10.9Hz,4H),1.52(q,J=11.3Hz,4H);MS(ESI)m/z:calculated for C25H22Cl2N4O4[M+H]+:513.10,found:513.3.。
实施例7
中间体5-(4-溴苯基)-1,3,4-噁二唑-2-甲酸乙酯的合成
步骤1:4-溴苯甲酰肼的合成
参照实施例3中步骤1所述的方法,得到白色固体267mg,产率53.40%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.87(s,1H),7.79-7.74(m,2H),7.69-7.64(m,2H),4.53(s,2H).
步骤2:2-(2-(4-溴苯甲酰基)肼基)-2-氧代乙酸乙酯的合成
参照实施例3中步骤2所述的方法,得到白色固体252mg,产率85.99%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.99(s,1H),10.75-10.68(m,1H),7.85-7.80(m,2H),7.78-7.73(m,2H),4.31(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).
步骤3:5-(4-溴苯基)-1,3,4-噁二唑-2-甲酸乙酯的合成
参照实施例3中步骤3所述的方法,得到白色固体153mg,产率65.70%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.05-7.98(m,2H),7.90-7.84(m,2H),4.46(q,J=7.1Hz,2H),1.37(t,J=7.1Hz,3H).。
实施例8
反-5-(4-溴苯基)-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-3)的合成
步骤1:5-(4-溴苯基)-1,3,4-噁二唑-2-羧酸的合成
参照实施例1中步骤2所述的方法,得到白色固体102mg,产率73.62%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.39(s,1H),8.00-7.95(m,2H),7.86 -7.81(m,2H).
步骤2:反-5-(4-溴苯基)-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-3)的合成
参照实施例4中步骤2所述的方法,得到白色固体85mg,产率27.31%。1H NMR(300MHz,DMSO-d6)δ(ppm)9.30(d,J=8.2Hz,1H),8.68(d,J=8.1Hz,1H),8.09-8.00(m,2H),7.93-7.83(m,3H),7.71(d,J=8.8Hz,1H),7.54(d,J=0.9Hz,1H),7.49(dd,J=8.8,2.2Hz,1H),3.79(d,J=8.3Hz,2H),1.91(d,J=9.1Hz,4H),1.56(q,J=9.7Hz,4H);MS(ESI)m/z:calculated for C24H20BrClN4O4[M+H]+:543.04,found:543.0428.。
实施例9
中间体5-(4-氯-3-氟苯基)-1,3,4-噁二唑-2-甲酸乙酯的合成
步骤1:3-氟-4-氯苯甲酰肼的合成
参照实施例3中步骤1所述的方法,得到白色固体1.73g,产率91.88%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.95(s,1H),7.85-7.76(m,1H),7.75-7.66(m,2H),4.47(s,2H).
步骤2:2-(2-(4-氯-3-氟苯甲酰基)肼基)-2-氧代乙酸乙酯的合成
参照实施例3中步骤2所述的方法,得到白色固体540mg,产率69.86%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.91(s,2H),7.90-7.84(m,1H),7.83-7.76(m,2H),4.31(q,J=7.1Hz,2H),1.31(t,J=7.1Hz,3H).
步骤3:5-(4-氯-3-氟苯基)-1,3,4-噁二唑-2-甲酸乙酯的合成
参照实施例3中步骤3所述的方法,得到白色固体376mg,产率74.26%。1H NMR(300MHz,Chloroform-d)δ(ppm):8.00-7.92(m,2H),7.66 -7.59(m,1H),4.58(q,J=7.2Hz,2H),1.51(t,J=7.1Hz,3H).。
实施例10
反-5-(4-氯-3-氟苯基)-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-4)的合成
步骤1:5-(4-氯-3-氟苯基)-1,3,4-噁二唑-2-羧酸的合成
参照实施例1中步骤2所述的方法,得到白色固体243mg,产率70.38%。1H NMR(300MHz,Methanol-d4)δ(ppm):8.05-7.94(m,2H),7.74(dd,J=8.4,7.4Hz,1H).
步骤2:反-5-(4-氯-3-氟苯基)-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-4)的合成
参照实施例4中步骤2所述的方法,得到白色固体104mg,产率29.43%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.28(d,J=8.1Hz,1H),8.65(d,J=8.1Hz,1H),8.11(dd,J=9.6,1.9Hz,1H),7.97(dd,J=8.5,1.9Hz,1H),7.93 -7.86(m,2H),7.71(d,J=8.8Hz,1H),7.54(d,J=0.9Hz,1H),7.49(dd,J=8.9,2.2Hz,1H),3.81(s,2H),1.92(d,J=8.9Hz,4H),1.56(q,J=9.8Hz,4H);MS(ESI)m/z:calculated for C24H19ClFN4O4[M+H]+:517.08,found:517.1.。
实施例11
中间体3-(4-氯苯基)-1,2,4-噁二唑-5-羧酸的合成
步骤1:(Z)-4-氯-N'-羟基苯甲酰胺的合成
将4-氯苯腈(0.30g,2.18mmol)溶于甲醇(10mL)中,盐酸羟胺(227mg,3.27mmol)和碳酸钠(173mg,1.64mmol)溶于水(1mL)并加入4-氯苯腈的甲醇溶液中,升温至65℃反应15h。将反应液减压浓缩,乙酸乙酯萃取,无水硫酸钠干燥,经减压浓缩,得到粗品黄色固体337mg,产率90.58%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.85(s,1H),7.88-7.80(m,2H),7.58-7.50(m,2H),4.51(s,2H).
步骤2:3-(4-氯苯基)-1,2,4-噁二唑-5-甲酸乙酯的合成
将(Z)-4-氯-N'-羟基苯甲酰胺(337mg,1.98mmol)溶于四氢呋喃中,加入N,N-二异丙基乙胺(412μl,2.96mmol),缓慢加入草酰氯单乙酯(405mg,2.96mmol),升温至70℃,反应2h。将反应液减压浓缩,乙酸乙酯萃取,无水硫酸钠干燥,过滤,滤液经减压浓缩,残留物通过硅胶柱层析(石油醚/乙酸乙酯=150/1~50/1)纯化得白色固体331mg,产率66.32%。1HNMR(300MHz,DMSO-d6)δ(ppm):8.13-8.05(m,2H),7.77-7.64(m,2H),4.47(q,J=7.1Hz,2H),1.38(t,J=7.1Hz,3H).
步骤3:3-(4-氯苯基)-1,2,4-噁二唑-5-羧酸的合成
参照实施例1中步骤2所述的方法,得到白色固体147mg,产率49.96%。1H NMR(300MHz,Methanol-d4)δ(ppm):8.15-8.09(m,2H),7.60-7.54(m,2H).。
实施例12
反-N-(4-(5-氯苯并呋喃-2-甲酰胺基)环己基)-3-(4-氯苯基)-1,2,4-噁二唑-5-甲酰胺(Ⅰ-5)的合成
参照实施例4中步骤2所述的方法,得到白色固体107mg,产率42.39%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.42(d,J=8.2Hz,1H),8.66(d,J=8.1Hz,1H),8.13-8.06(m,2H),7.88(d,J=2.2Hz,1H),7.70(dt,J=9.2,2.4Hz,3H),7.54(d,J=0.9Hz,1H),7.49(dd,J=8.8,2.2Hz,1H),3.87-3.74(m,2H),1.96-1.85(m,4H),1.56(q,J=9.7Hz,4H);MS(ESI)m/z:calculated for C24H20Cl2N4O4[M+H]+:499.09,found:499.0934.。
实施例13
反-5-氯-N-(4-(((5-(4-氯苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)苯并呋喃-2-甲酰胺(Ⅰ-6)的合成
步骤1:4-氯-N'-(2-氯乙酰基)苯甲酰肼的合成
将4-氯苯甲酰肼(1.92g,11.28mmol)溶于二氯甲烷(20mL)中,加入DIPEA(2.92g,22.56mmol),加入氯乙酰氯(1.35mL,16.92mmol),室温下反应50min。将反应液减压浓缩,用水搅拌洗涤,过滤,滤饼用石油醚/乙酸乙酯洗涤,过滤,滤饼干燥,得到白色固体2.11g,产率75.72%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.64(s,1H),10.42(s,1H),7.90(d,J=8.3Hz,2H),7.60(d,J=8.2Hz,2H),4.22(s,2H).
步骤2:2-(氯甲基)-5-(4-氯苯基)-1,3,4-噁二唑的合成
将4-氯-N'-(2-氯乙酰基)苯甲酰肼(1.78g,7.20mmol)溶于乙腈(15mL)中,加入POCl3(2.01mL,21.59mmol),封管反应并升温至85℃,反应10h。缓慢加入水,用乙酸乙酯萃取,无水硫酸钠干燥,过滤,滤液经减压浓缩,残留物通过硅胶柱层析(石油醚/乙酸乙酯=80/1)纯化得到白色固体856mg,产率51.93%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.09-8.00(m,2H),7.77-7.67(m,2H),5.16(s,2H).
步骤3:反-5-氯-N-(4-(((5-(4-氯苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)苯并呋喃-2-甲酰胺(Ⅰ-6)的合成
将2-(氯甲基)-5-(4-氯苯基)-1,3,4-噁二唑(132mg,450μmol)溶于N,N-二甲基甲酰胺(10mL)中,加入碳酸钾(124mg,900μmol)室温搅拌10min,接着缓慢加入N-(4-氨基环己基)-5-氯苯并呋喃-2-甲酰胺(103mg,450μmol),室温反应4h。用乙酸乙酯萃取,无水硫酸钠干燥,经减压浓缩,残留物通过硅胶柱层析(二氯甲烷/甲醇=100/1)纯化得到白色固体67mg,产率30.70%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.57(d,J=8.1Hz,1H),8.05-7.99(m,2H),7.86(d,J=2.2Hz,1H),7.70(dt,J=8.9,2.4Hz,3H),7.51(d,J=0.9Hz,1H),7.47(dd,J=8.9,2.2Hz,1H),4.05(s,2H),3.81-3.70(m,1H),2.44(d,J=10.7Hz,1H),2.00-1.91(m,2H),1.83(d,J=12.3Hz,2H),1.47-1.34(m,2H),1.21 -1.10(m,2H);MS(ESI)m/z:calculated for C24H22Cl2N4O3[M+H]+:485.11,found:485.1133.。
实施例14
反-5-氯-N-(4-(((5-(4-氯苄基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)苯并呋喃-2-甲酰胺(Ⅰ-7)的合成
步骤1:2-氯-N'-(2-(4-氯苯基)乙酰基)乙酰肼的合成
参照实施例13中步骤1所述的方法,得到淡黄色固体710mg,产率83.67%。1H NMR(300MHz,,DMSO-d6)δ(ppm):10.38-10.29(m,2H),7.41-7.37(m,2H),7.32(d,J=8.5Hz,2H),4.14(s,2H),3.51(s,2H).
步骤2:2-(4-氯苄基)-5-(氯甲基)-1,3,4-噁二唑的合成
参照实施例13中步骤2所述的方法,得到白色固体282mg,产率59.63%。1H NMR(300MHz,DMSO-d6)δ(ppm):7.47-7.41(m,2H),7.40-7.35(m,2H),5.03(s,2H),4.35(s,2H).
步骤3:反-5-氯-N-(4-(((5-(4-氯苄基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)苯并呋喃-2-甲酰胺(Ⅰ-7)的合成
参照实施例13中步骤3所述的方法,得到白色固体89mg,产率29.08%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.55(d,J=8.1Hz,1H),7.85(d,J=2.2Hz,1H),7.68(d,J=8.8Hz,1H),7.51(d,J=1.0Hz,1H),7.49 -7.40(m,3H),7.37 -7.31(m,2H),4.28(s,2H),3.90(s,2H),3.77-3.65(m,1H),2.33(d,J=11.0Hz,1H),1.90-1.75(m,4H),1.36(q,J=11.9Hz,2H),1.07(q,J=11.4Hz,2H);MS(ESI)m/z:calculated for C24H22Cl2N4O3[M+H]+:499.12,found:499.1303.。
实施例15
反-N-(4-(((5-(4-溴苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)-5-氯苯并呋喃-2-甲酰胺(Ⅰ-8)的合成
步骤1:4-溴-N'-(2-氯乙酰基)苯甲酰肼的合成
参照实施例13中步骤1所述的方法,得到白色固体163mg,产率45.03%。
步骤2:2-(4-溴苯基)-5-(氯甲基)-1,3,4-噁二唑的合成
参照实施例13中步骤2所述的方法,得到白色固体86mg,产率89.87%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.00-7.92(m,2H),7.88-7.79(m,2H),5.15(s,2H).
步骤3:反-N-(4-(((5-(4-溴苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)-5-氯苯并呋喃-2-甲酰胺(Ⅰ-8)的合成
参照实施例13中步骤3所述的方法,得到白色固体108mg,产率29.34%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.58(d,J=8.1Hz,1H),7.99-7.92(m,2H),7.89 -7.81(m,3H),7.69(d,J=8.8Hz,1H),7.52(d,J=0.9Hz,1H),7.47(dd,J=8.9,2.2Hz,1H),4.05(s,2H),3.81-3.69(m,1H),2.44(d,J=10.7Hz,1H),2.00-1.91(m,2H),1.83(d,J=12.4Hz,2H),1.45-1.32(m,2H),1.24-1.14(m,2H);MS(ESI)m/z:calculated for C24H22BrClN4O3[M+H]+:529.06,found:529.0640.。
实施例16
反-5-氯-N-(4-(((5-(4-氯-3-氟苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)苯并呋喃-2-甲酰胺(Ⅰ-9)的合成
步骤1:4-氯-N'-(2-氯乙酰基)-3-氟苯甲酰肼的合成
参照实施例13中步骤1所述的方法,得到白色固体613mg,产率86.19%。
步骤2:2-(4-氯-3-氟苯基)-5-(氯甲基)-1,3,4-噁二唑的合成
参照实施例13中步骤2所述的方法,得到白色固体306mg,产率53.56%。1H NMR(300MHz,Chloroform-d)δ(ppm):7.92-7.83(m,2H),7.64 -7.55(m,1H),4.81(s,2H).
步骤3:反-5-氯-N-(4-(((5-(4-氯-3-氟苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)苯并呋喃-2-甲酰胺(Ⅰ-9)的合成
参照实施例13中步骤3所述的方法,得到白色固体84mg,产率27.30%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.59(d,J=8.1Hz,1H),8.04-7.97(m,1H),7.87(dd,J=3.7,1.4Hz,3H),7.69(d,J=8.8Hz,1H),7.51(d,J=0.9Hz,1H),7.47(dd,J=8.8,2.2Hz,1H),4.06(s,2H),3.75(dt,J=7.8,3.8Hz,1H),2.44(d,J=10.9Hz,1H),1.96(d,J=12.6Hz,2H),1.83(d,J=11.9Hz,2H),1.48-1.36(m,2H),1.14(d,J=13.0Hz,2H);MS(ESI)m/z:calculated for C24H21Cl2FN4O3[M+H]+:503.10,found:503.2.。
实施例17
中间体(1-(5-氯苯并呋喃-2-甲酰胺基)哌啶-4-基)氨基甲酸叔丁酯的合成
步骤1:(1-亚硝基哌啶-4-基)氨基甲酸叔丁酯的合成
将N-Boc-氨基哌啶(300mg,1.50mmol)溶于四氢呋喃(10mL)中,在冰浴条件下滴入1mol/L盐酸(2.70mL,2.70mmol),接着缓慢加入溶于5mL水的亚硝酸钠(248mg,3.59mmol)。反应3h。用乙酸乙酯和水萃取,无水硫酸钠干燥,过滤,滤液经减压浓缩,得到白色固体315mg,产率91.72%。无需进一步处理,直接用于下一步反应。
步骤2:(1-氨基哌啶-4-基)氨基甲酸叔丁酯的合成
将(1-亚硝基哌啶-4-基)氨基甲酸叔丁酯(340mg,1.48mmol)溶于乙酸/水(1:1,15mL)中,加入锌粉(383mg,5.93mmol),保持0℃反应。反应12h。将反应液抽滤,滤液浓缩,加入乙酸乙酯(30mL)洗涤,搅拌30min,抽滤,将滤液浓缩,干燥,得到透明油状液体251mg,产率78.62%,无需进一步处理,直接用于下一步反应。
步骤3:(1-(5-氯苯并呋喃-2-甲酰胺基)哌啶-4-基)氨基甲酸叔丁酯的合成
将5-氯苯并呋喃-2-羧酸(114mg,0.58mmol)溶于N,N-二甲基甲酰胺(5mL),依次加入HATU(331mg,0.87mmol)和N,N-二异丙基乙胺(0.30mL,1.74mmol),室温搅拌15min后,接着加入(1-氨基哌啶-4-基)氨基甲酸叔丁酯(125mg,0.58mmol)。反应10h。向反应液中加入水,搅拌10min,抽滤,用少量乙酸乙酯洗涤,得到白色固体123mg,产率53.79%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.77(s,1H),7.95(s,1H),7.86(d,J=2.2Hz,1H),7.70(d,J=8.8Hz,1H),7.53-7.45(m,2H),6.85(d,J=7.8Hz,1H),2.96(d,J=10.5Hz,2H),2.78-2.66(m,4H),1.75(d,J=12.5Hz,2H),1.61-1.47(m,2H),1.39(s,9H).。
实施例18
N-(1-(5-氯苯并呋喃-2-甲酰胺基)哌啶-4-基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(I-10)的合成
步骤1:N-(4-氨基哌啶-1-基)-5-氯苯并呋喃-2-甲酰胺的合成
参照实施例2中所述的方法,得到淡黄色固体50mg,产率50.54%。1H NMR(300MHz,Chloroform-d)δ(ppm):7.66(d,J=2.0Hz,1H),7.48(d,J=0.8Hz,1H),7.46-7.35(m,3H),3.25(dt,J=10.6,3.9Hz,2H),2.86(dq,J=10.2,6.3,5.2Hz,1H),2.75(td,J=11.0,2.8Hz,2H),1.96(d,J=3.8Hz,2H),1.75-1.67(m,2H).
步骤2:N-(1-(5-氯苯并呋喃-2-甲酰胺基)哌啶-4-基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(I-10)的合成
将5-(4-氯苯基)-1,3,4-噁二唑-2-羧酸(39mg,0.17mmol)溶于溶于N,N-二甲基甲酰胺(5mL),依次加入HATU(84mg,0.22mmol)和N-(4-氨基哌啶-1-基)-5-氯苯并呋喃-2-甲酰胺(50mg,0.17mmol),室温搅拌5min后,接着加入N,N-二异丙基乙胺(74μL,0.43mmol)。反应6h。用二氯甲烷萃取,无水硫酸钠干燥,过滤,滤液经减压浓缩,残留物通过硅胶柱层析(二氯甲烷/甲醇=200/1~100/1)纯化得到白色固体21mg,产率24.66%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.84(s,1H),9.39(d,J=8.0Hz,1H),8.11(d,J=8.2Hz,2H),7.88(s,1H),7.72(t,J=8.1Hz,3H),7.55-7.45(m,2H),3.85(s,1H),3.06(d,J=10.3Hz,2H),2.83(s,2H),1.85(s,4H);MS(ESI)m/z:calculated for C23H19Cl2N5O4[M+H]+:500.08,found:500.1.。
实施例19
N-(1-(5-氯苯并呋喃-2-甲酰胺)哌啶-4-基)-5-(4-氯苄基)-1,3,4-噁二唑-2-甲酰胺(I-11)的合成
参照实施例18中步骤2所述的方法,得到白色固体34mg,产率26.60%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.82(s,1H),9.31(d,J=8.1Hz,1H),7.87(d,J=2.2Hz,1H),7.70(d,J=8.9Hz,1H),7.56-7.46(m,3H),7.46-7.42(m,2H),7.39(d,J=8.5Hz,2H),4.39(s,2H),3.78(q,J=7.8Hz,1H),3.02(d,J=10.9Hz,2H),2.84 -2.75(m,2H),1.80(s,4H);MS(ESI)m/z:calculated for C24H21Cl2N5O4[M+H]+:514.10,found:514.5.。
实施例20
中间体((1-(5-氯苯并呋喃-2-甲酰胺基)哌啶-4-基)甲基)氨基甲酸叔丁酯的合成
步骤1:((1-亚硝基哌啶-4-基)甲基)氨基甲酸叔丁酯的合成
参照实施例17中步骤1所述的方法,得到白色固体876mg,产率96.45%。无需进一步处理,直接用于下一步反应。
步骤2:((1-氨基哌啶-4-基)甲基)氨基甲酸叔丁酯的合成
参照实施例17中步骤2所述的方法,得到透明油状液体671mg,产率81.27%。无需进一步处理,直接用于下一步反应。
步骤3:((1-(5-氯苯并呋喃-2-甲酰胺基)哌啶-4-基)甲基)氨基甲酸叔丁酯的合成
参照实施例17中步骤3所述的方法,得到白色固体151mg,产率42.45%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.73(s,1H),7.86(d,J=2.2Hz,1H),7.70(d,J=8.8Hz,1H),7.53-7.45(m,2H),6.87(t,J=5.8Hz,1H),2.99(d,J=10.4Hz,2H),2.85(t,J=6.1Hz,2H),2.75-2.60(m,2H),1.65(d,J=12.8Hz,2H),1.39(s,9H),1.35-1.14(m,3H).。
实施例21
N-((1-(5-氯苯并呋喃-2-甲酰胺)哌啶-4-基)甲基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(I-12)的合成
步骤1:N-(4-(氨基甲基)哌啶-1-基)-5-氯苯并呋喃-2-甲酰胺的合成
参照实施例2中所述的方法,得到白色固体97mg,产率85.70%。;MS(ESI)m/z:calculated for C15H18ClN3O2[M+H]+:308.1,found:308.3.
步骤5:N-((1-(5-氯苯并呋喃-2-甲酰胺)哌啶-4-基)甲基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(I-12)的合成
参照实施例18中步骤2所述的方法,得到白色固体41mg,产率49.07%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.76(s,1H),9.42(t,J=6.1Hz,1H),8.14-8.08(m,2H),7.86(d,J=2.2Hz,1H),7.75-7.68(m,3H),7.51(s,1H),7.48(dd,J=8.9,2.3Hz,1H),3.24(t,J=6.4Hz,2H),3.03(d,J=10.3Hz,2H),2.70(t,J=10.9Hz,2H),1.75(d,J=12.9Hz,2H),1.65(s,1H),1.36(t,J=11.3Hz,2H);MS(ESI)m/z:calculated for C24H21Cl2N5O4[M+H]+:514.10,found:514.2.。
实施例22
N-((1-(5-氯苯并呋喃-2-甲酰胺基)哌啶-4-基)甲基)-5-(4-氯苄基)-1,3,4-噁二唑-2-甲酰胺(I-13)的合成
参照实施例18中步骤2所述的方法,得到白色固体34mg,产率39.61%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.77(s,1H),9.34(t,J=6.0Hz,1H),7.87(d,J=2.3Hz,1H),7.70(d,J=8.9Hz,1H),7.52-7.42(m,4H),7.39(d,J=8.6Hz,2H),4.39(s,2H),3.17(t,J=6.3Hz,2H),3.00(d,J=10.8Hz,2H),2.76-2.61(m,2H),1.70(d,J=13.4Hz,2H),1.60(s,1H),1.33(d,J=14.8Hz,2H);MS(ESI)m/z:calculated for C25H23Cl2N5O4[M+H]+:528.11,found:528.5.。
实施例23
5-(4-溴苯基)-N-((1-(5-氯苯并呋喃-2-甲酰胺基)哌啶-4-基)甲基)-1,3,4-噁二唑-2-甲酰胺(I-14)的合成
参照实施例18中步骤2所述的方法,得到白色固体48mg,产率46.38%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.78(s,1H),9.44(t,J=6.0Hz,1H),8.08-7.99(m,2H),7.87(dt,J=6.6,2.5Hz,3H),7.70(d,J=8.9Hz,1H),7.52-7.45(m,2H),3.24(t,J=6.3Hz,2H),3.02(d,J=10.2Hz,2H),2.76-2.66(m,2H),1.75(d,J=13.1Hz,2H),1.64(s,1H),1.41-1.31(m,2H);MS(ESI)m/z:calculated for C24H21BrClN5O4[M+H]+:558.05,found:558.4.。
实施例24
5-(4-氯-3-氟苯基)-N-((1-(5-氯苯并呋喃-2-甲酰胺)哌啶-4-基)甲基)-1,3,4-噁二唑-2-甲酰胺(I-15)的合成
参照实施例18中步骤2所述的方法,得到白色固体30mg,产率29.40%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.78(s,1H),9.45(t,J=6.0Hz,1H),8.11(dd,J=9.5,1.9Hz,1H),7.96(dd,J=8.5,1.9Hz,1H),7.91(d,J=7.4Hz,1H),7.89-7.85(m,1H),7.70(d,J=8.8Hz,1H),7.54-7.45(m,2H),3.24(t,J=6.5Hz,2H),3.02(d,J=10.3Hz,2H),2.74-2.65(m,2H),1.75(d,J=12.9Hz,2H),1.65(s,1H),1.36(t,J=10.8Hz,2H);MS(ESI)m/z:calculated for C24H20Cl2FN5O4[M+H]+:532.09,found:532.4.。
实施例25
N-(1-(5-氯苯并呋喃-2-羰基)哌啶-4-基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(I-16)的合成
步骤1:(1-(5-氯苯并呋喃-2-羰基)哌啶-4-基)氨基甲酸叔丁酯的合成
将5-氯苯并呋喃-2-羧酸(200mg,1.02mmol)溶于N,N-二甲基甲酰胺(5mL),依次加入HATU(774mg,2.03mmol)和N,N-二异丙基乙胺(0.53mL,3.05mmol),室温搅拌15min后,接着加入N-Boc氨基哌啶(214mg,1.07mmol),反应4.5h。用乙酸乙酯萃取,无水硫酸钠干燥,经减压浓缩,残留物通过硅胶柱层析(石油醚/乙酸乙酯=5/1)纯化得到乳白色固体141mg,产率36.58%。1H NMR(300MHz,Chloroform-d)δ(ppm):7.64(dd,J=2.2,0.6Hz,1H),7.47(dt,J=8.8,0.8Hz,1H),7.37(dd,J=8.8,2.1Hz,1H),7.23(d,J=0.9Hz,1H),6.82(d,J=8.1Hz,1H),4.52(s,2H),3.88-3.68(m,1H),3.35-2.92(m,2H),2.17-2.02(m,2H),1.67(d,J=17.8Hz,2H),1.47(s,9H).
步骤2:(4-氨基哌啶-1-基)(5-氯苯并呋喃-2-基)甲酮的合成
参照实施例2所述的方法,通过硅胶柱层析(二氯甲烷/甲醇=100/1)纯化得到白色固体62mg,产率59.77%。1H NMR(300MHz,DMSO-d6)δ(ppm):7.82(d,J=2.2Hz,1H),7.72(d,J=8.8Hz,1H),7.47(dd,J=8.9,2.2Hz,1H),7.32(s,1H),4.04(s,2H),3.08 -2.82(m,3H),1.84-1.75(m,2H),1.28-1.18(m,2H).
步骤3:N-(1-(5-氯苯并呋喃-2-羰基)哌啶-4-基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(Ⅱ-7)的合成
参照实施例18中步骤2所述的方法,通过硅胶柱层析(石油醚/乙酸乙酯=2/1)纯化得到白色固体145mg,产率64.06%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.38(d,J=8.0Hz,1H),8.15-8.08(m,2H),7.84(d,J=2.2Hz,1H),7.73(dd,J=8.8,2.7Hz,3H),7.48(dd,J=8.8,2.3Hz,1H),7.37(s,1H),4.33-4.13(m,2H),3.03(s,1H),1.94(d,J=12.8Hz,2H),1.67(qd,J=12.2,11.5,3.6Hz,2H),1.25(q,J=5.5,4.0Hz,2H);MS(ESI)m/z:calculated forC23H18Cl2N4O4[M+H]+:485.07,found:485.4.。
实施例26
N-((1-(5-氯苯并呋喃-2-羰基)哌啶-4-基)甲基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(I-17)的合成
步骤1:((1-(5-氯苯并呋喃-2-羰基)哌啶-4-基)甲基)氨基甲酸叔丁酯的合成
参照实施例25中步骤1所述的方法,得到淡黄色固体176mg,产率41.92%。1H NMR(300MHz,Chloroform-d)δ(ppm):7.66-7.61(m,1H),7.47(dt,J=8.8,0.7Hz,1H),7.36(dd,J=8.8,2.1Hz,1H),7.20(d,J=0.9Hz,1H),6.83(d,J=8.2Hz,1H),4.69(s,2H),3.09(s,3H),1.85(d,J=12.4Hz,3H),1.47(s,9H),1.37-1.26(m,2H).
步骤2:(4-(氨基甲基)哌啶-1-基)(5-氯苯并呋喃-2-基)甲酮的合成
参照实施例2所述的方法,通过硅胶柱层析(二氯甲烷/甲醇=75/1)纯化得到透明油状液体107mg,产率81.59%。1H NMR(300MHz,Chloroform-d)δ(ppm):7.63(dd,J=2.2,0.6Hz,1H),7.47(dt,J=8.8,0.8Hz,1H),7.36(dd,J=8.8,2.1Hz,1H),7.20(d,J=0.9Hz,1H),4.58(d,J=70.8Hz,2H),3.01(d,J=93.7Hz,2H),2.68(d,J=6.5Hz,2H),1.90(d,J=12.8Hz,2H),1.76(s,3H),1.29(dt,J=9.6,2.6Hz,2H).
步骤3:N-((1-(5-氯苯并呋喃-2-羰基)哌啶-4-基)甲基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(I-17)的合成
参照实施例18中步骤2所述的方法,通过硅胶柱层析(石油醚/乙酸乙酯=20/1)纯化得到白色固体34mg,产率18.63%。1H NMR(400MHz,Chloroform-d)δ(ppm):8.17-8.08(m,2H),7.64(d,J=2.1Hz,1H),7.60-7.52(m,2H),7.47(d,J=8.8Hz,1H),7.39-7.31(m,2H),7.23(d,J=0.9Hz,1H),4.62(d,J=79.4Hz,2H),3.49(s,2H),2.97(d,J=67.1Hz,2H),2.09-2.01(m,1H),1.95(d,J=13.4Hz,2H),1.47-1.39(m,2H);MS(ESI)m/z:calculatedfor C24H20Cl2N4O4[M+H]+:499.09,found:499.2.。
实施例27
5-氯-N-(1-(5-(4-氯苯基)-1,3,4-噁二唑-2-羰基)哌啶-4-基)苯并呋喃-2-甲酰胺(I-18)的合成
步骤1:4-(5-氯苯并呋喃-2-甲酰胺基)哌啶-1-羧酸叔丁酯的合成
参照实施例25中步骤1所述的方法,得到黄色固体280mg,产率72.65%.1H NMR(300MHz,Chloroform-d)δ(ppm):7.67(dd,J=2.1,0.6Hz,1H),7.48-7.42(m,2H),7.39(dd,J=8.7,2.1Hz,1H),6.52(d,J=8.2Hz,1H),4.17(dddd,J=15.6,11.8,7.8,4.3Hz,3H),3.02-2.90(m,2H),2.05(dd,J=12.9,3.7Hz,2H),1.71(d,J=6.7Hz,2H),1.47(s,9H).
步骤2:5-氯-N-(哌啶-4-基)苯并呋喃-2-甲酰胺的合成
参照实施例2所述的方法,通过硅胶柱层析(二氯甲烷/甲醇=50/1)纯化得到白色固体162mg,产率78.64%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.67(d,J=8.0Hz,1H),7.87(d,J=2.2Hz,1H),7.70(d,J=8.9Hz,1H),7.54(d,J=0.9Hz,1H),7.48(dd,J=8.8,2.2Hz,1H),3.85(dtd,J=11.6,7.5,4.0Hz,1H),3.05-2.93(m,2H),2.57(dd,J=12.3,2.5Hz,2H),1.79-1.69(m,2H),1.48(qd,J=12.1,4.1Hz,2H),1.24(dd,J=6.9,2.6Hz,1H).
步骤3:5-氯-N-(1-(5-(4-氯苯基)-1,3,4-噁二唑-2-羰基)哌啶-4-基)苯并呋喃-2-甲酰胺(I-18)的合成
参照实施例18中步骤2所述的方法,通过硅胶柱层析(石油醚/乙酸乙酯=1/1)纯化得到淡黄色固体154mg,产率54.60%。1H NMR(400MHz,DMSO-d6)δ(ppm):8.80(d,J=8.0Hz,1H),8.11-8.05(m,2H),7.88(d,J=2.2Hz,1H),7.75-7.68(m,3H),7.56(d,J=0.9Hz,1H),7.49(dd,J=8.9,2.3Hz,1H),4.52(dd,J=27.4,13.6Hz,2H),4.20(dtt,J=11.3,8.0,4.0Hz,1H),3.49-3.41(m,1H),3.16-3.08(m,1H),1.97(td,J=16.5,15.8,3.9Hz,2H),1.73 -1.56(m,2H);MS(ESI)m/z:calculated for C23H18Cl2N4O4[M+H]+:485.07,found:485.2.。
实施例28
5-氯-N-((1-(5-(4-氯苯基)-1,3,4-噁二唑-2-羰基)哌啶-4-基)甲基)苯并呋喃-2-甲酰胺(I-19)的合成
步骤1:4-((5-氯苯并呋喃-2-甲酰胺基)甲基)哌啶-1-羧酸叔丁酯的合成
参照实施例25中步骤1所述的方法,得到淡黄色固体226mg,产率61.64%。1H NMR(400MHz,Chloroform-d)δ(ppm):7.69 -7.66(m,1H),7.46 -7.43(m,2H),7.39(dd,J=8.7,2.1Hz,1H),6.75(d,J=6.7Hz,1H),4.16(s,2H),3.41(s,2H),2.71(d,J=13.4Hz,2H),1.85(ddd,J=10.4,7.0,3.5Hz,1H),1.78(d,J=13.8Hz,2H),1.47(s,9H),1.26(ddd,J=16.3,10.0,4.2Hz,2H).
步骤2:5-氯-N-(哌啶-4-基甲基)苯并呋喃-2-甲酰胺的合成
参照实施例2所述的方法,得到白色固体66mg,产率39.19%。1H NMR(300MHz,Chloroform-d)δ(ppm):7.67(d,J=1.9Hz,1H),7.47-7.41(m,2H),7.39(dd,J=8.8,2.1Hz,1H),6.74(s,1H),3.40(t,J=6.2Hz,2H),3.15(dt,J=12.3,3.4Hz,2H),2.64(td,J=12.2,2.3Hz,2H),2.16(s,2H),1.79(dt,J=12.3,3.5Hz,3H),1.33-1.28(m,1H).
步骤3:5-氯-N-((1-(5-(4-氯苯基)-1,3,4-噁二唑-2-羰基)哌啶-4-基)甲基)苯并呋喃-2-甲酰胺(I-19)的合成
参照实施例18中步骤2所述的方法,通过硅胶柱层析(石油醚/乙酸乙酯=1/1)纯化得到白色固体20mg,产率17.77%。1H NMR(400MHz,Chloroform-d)δ(ppm):8.13-8.08(m,2H),7.68(d,J=2.0Hz,1H),7.57-7.51(m,2H),7.44(s,2H),7.40(dd,J=8.9,2.1Hz,1H),6.80(t,J=6.3Hz,1H),5.03(ddt,J=13.7,4.5,2.4Hz,1H),4.81(ddt,J=13.5,4.6,2.4Hz,1H),3.46(t,J=6.6Hz,2H),3.36-3.23(m,1H),2.91(td,J=12.9,2.9Hz,1H),2.09(dqd,J=8.1,6.0,5.1,3.4Hz,1H),2.03-1.96(m,2H),1.44(tdd,J=13.1,8.7,4.9Hz,2H);MS(ESI)m/z:calculated for C24H20Cl2N4O4[M+H]+:499.09,found:499.2.。
实施例29
中间体反-(4-(6-氯喹啉-2-甲酰胺基)环己基)氨基甲酸叔丁酯的合成
步骤1:6-氯喹啉-2-甲醛的合成
将2-甲基-6-氯喹啉(200mg,1.13mmol)溶于1,4-二氧六环(5mL),加入二氧化锡(750mg,6.76mmol),升温至80℃反应3h。用硅藻土抽滤,滤液减压浓缩,干燥得到粉色固体198mg,产率91.78%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.12(d,J=0.8Hz,1H),8.59(d,J=8.5Hz,1H),8.31(d,J=2.4Hz,1H),8.26(d,J=9.0Hz,1H),8.05(d,J=8.5Hz,1H),7.94(dd,J=9.0,2.4Hz,1H).
步骤2:6-氯喹啉-2-羧酸的合成
将6-氯喹啉-2-甲醛(107mg,0.56mmol)溶于叔丁醇(10mL),再缓慢滴加溶解有亚氯酸钠(152mg,1.68mmol)和磷酸二氢钠(201mg,1.68mmol)的水溶液(5mL),反应10h。将亚硫酸钠(228mg,2.23mmol)溶于5mL水,接着缓慢加入反应液中淬灭反应。冷却至室温,缓慢滴加1mol/L盐酸,调节pH至4~5,抽滤,干燥,得白色固体73mg,产率62.97%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.54(d,J=8.6Hz,1H),8.26(d,J=2.4Hz,1H),8.17(dd,J=8.8,3.8Hz,2H),7.88(dd,J=9.0,2.4Hz,1H).
步骤3:反-(4-(6-氯喹啉-2-甲酰胺基)环己基)氨基甲酸叔丁酯的合成
参照实施例1中步骤3所述的方法,得到白色固体102mg,产率71.82%。1H NMR(400MHz,DMSO-d6)δ(ppm):8.68(d,J=8.5Hz,1H),8.54(d,J=8.5Hz,1H),8.25(d,J=2.4Hz,1H),8.18(dd,J=8.7,2.6Hz,2H),7.89(dd,J=9.0,2.4Hz,1H),6.79(d,J=8.0Hz,1H),3.83-3.71(m,1H),3.25-3.20(m,1H),1.85(d,J=11.3Hz,4H),1.55(q,J=12.5Hz,2H),1.39(s,9H),1.31-1.23(m,2H).。
实施例30
反-5-(4-氯苯基)-N-(4-(6-氯喹啉-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-20)的合成
步骤1:反-N-(4-氨基环己基)-6-氯喹啉-2-甲酰胺的合成
参照实施例2所述的方法,得到淡黄色固体167mg,产率73.52%。1H NMR(400MHz,DMSO-d6)δ(ppm):8.71(d,J=8.4Hz,1H),8.55(d,J=8.6Hz,1H),8.26(d,J=2.4Hz,1H),8.17(t,J=8.9Hz,2H),7.89(dd,J=9.0,2.5Hz,1H),3.82(dtd,J=12.0,8.2,4.3Hz,1H),3.08-2.95(m,1H),2.04-1.87(m,4H),1.64-1.39(m,4H).
步骤5:反-5-(4-氯苯基)-N-(4-(6-氯喹啉-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-20)的合成
参照实施例1中步骤3所述的方法,得到白色固体96mg,产率84.03%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.29(d,J=8.2Hz,1H),8.71(d,J=8.5Hz,1H),8.55(d,J=8.6Hz,1H),8.26(d,J=2.4Hz,1H),8.20(dd,J=8.8,4.6Hz,2H),8.15-8.08(m,2H),7.89(dd,J=9.0,2.4Hz,1H),7.76-7.70(m,2H),3.86(d,J=10.0Hz,2H),1.98 -1.89(m,4H),1.69-1.59(m,4H);MS(ESI)m/z:calculated for C25H21Cl2N5O3[M+H]+:510.10,found:510.5.。
实施例31
反-5-(4-氯苄基)-N-(4-(6-氯喹啉-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-21)的合成
参照实施例1中步骤3所述的方法,得到白色固体43mg,产率49.82%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.21(d,J=8.3Hz,1H),8.69(d,J=8.5Hz,1H),8.55(d,J=8.6Hz,1H),8.25(d,J=2.5Hz,1H),8.19(dd,J=8.8,4.9Hz,2H),7.88(dd,J=9.0,2.5Hz,1H),7.47-7.42(m,2H),7.41-7.37(m,2H),4.39(s,2H),3.81(s,2H),1.94-1.84(m,4H),1.60(q,J=11.9,11.1Hz,4H);MS(ESI)m/z:calculated for C26H23Cl2N5O3[M+H]+:524.12,found:524.5.。
实施例32
反-5-(4-溴苯基)-N-(4-(6-氯喹啉-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-22)的合成
参照实施例1中步骤3所述的方法,得到白色固体23mg,产率21.34%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.74(d,J=8.6Hz,1H),8.55(d,J=8.8Hz,1H),8.40(d,J=7.9Hz,1H),8.29-8.14(m,3H),7.90(d,J=9.1Hz,1H),7.81(d,J=8.5Hz,2H),7.68(d,J=8.0Hz,2H),3.84(s,2H),1.92(d,J=11.5Hz,4H),1.65(d,J=12.5Hz,2H),1.49(d,J=12.3Hz,2H);MS(ESI)m/z:calculated for C25H21BrClN5O3[M+H]+:554.05,found:554.1.。
实施例33
反-5-(4-氯-3-氟苯基)-N-(4-(6-氯喹啉-2-甲酰胺基)环己基)-1,3,4-噁二唑-2-甲酰胺(Ⅰ-23)的合成
参照实施例1中步骤3所述的方法,得到白色固体47mg,产率54.05%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.30(d,J=8.2Hz,1H),8.71(d,J=8.4Hz,1H),8.55(d,J=8.5Hz,1H),8.25(d,J=2.4Hz,1H),8.20(dd,J=8.8,4.7Hz,2H),8.12(dd,J=9.5,1.9Hz,1H),7.97(dd,J=8.4,1.9Hz,1H),7.93-7.87(m,2H),3.94-3.81(m,2H),1.94(d,J=8.3Hz,4H),1.70-1.59(m,4H);MS(ESI)m/z:calculated for C25H20Cl2FN5O3[M+H]+:528.09,found:528.4.。
实施例34
反-3-(4-氯苯基)-N-(4-(6-氯喹啉-2-甲酰胺基)环己基)-1,2,4-噁二唑-5-甲酰胺(Ⅰ-24)的合成
参照实施例1中步骤3所述的方法,得到白色固体57mg,产率53.85%。1H NMR(400MHz,DMSO-d6)δ(ppm):9.43(d,J=8.2Hz,1H),8.71(d,J=8.5Hz,1H),8.55(d,J=8.6Hz,1H),8.26(d,J=2.4Hz,1H),8.20(dd,J=8.8,4.6Hz,2H),8.12-8.07(m,2H),7.89(dd,J=9.0,2.4Hz,1H),7.73-7.69(m,2H),3.86(s,2H),1.94(d,J=7.9Hz,4H),1.65(q,J=9.9,8.4Hz,4H);MS(ESI)m/z:calculated for C25H21Cl2N5O3[M+H]+:510.10,found:510.4.。
实施例35
反-6-氯-N-(4-(((5-(4-氯苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)喹啉-2-甲酰胺(Ⅰ-25)的合成
参照实施例13中步骤3所述的方法,得到白色固体34mg,产率49.36%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.68(d,J=8.5Hz,1H),8.54(d,J=8.7Hz,1H),8.25(d,J=2.4Hz,1H),8.18(dd,J=8.8,3.0Hz,2H),8.05-7.99(m,2H),7.88(dd,J=9.1,2.4Hz,1H),7.74-7.69(m,2H),5.33(s,2H),3.80(d,J=10.4Hz,1H),2.00(d,J=6.8Hz,1H),1.88(d,J=11.8Hz,4H),1.64-1.51(m,2H),1.36(t,J=11.9Hz,2H).;MS(ESI)m/z:calculated forC25H23Cl2N5O2[M+H]+:496.12,found:496.2.。
实施例36
反-6-氯-N-(4-(((5-(4-氯苄基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)喹啉-2-甲酰胺(Ⅰ-26)的合成
参照实施例13中步骤3所述的方法,得到白色固体88mg,产率65.47%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.62(d,J=8.5Hz,1H),8.54(d,J=8.6Hz,1H),8.25(d,J=2.4Hz,1H),8.17(dd,J=8.8,6.2Hz,2H),7.88(dd,J=9.1,2.4Hz,1H),7.46-7.42(m,2H),7.38-7.33(m,2H),4.29(s,2H),3.92(s,2H),3.80(d,J=11.5Hz,1H),2.41-2.32(m,1H),1.92-1.80(m,4H),1.51-1.40(m,2H),1.12(dd,J=14.8,4.5Hz,2H);MS(ESI)m/z:calculated for C26H25Cl2N5O2[M+H]+:510.14,found:510.5.。
实施例37
反-N-(4-(((5-(4-溴苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)-6-氯喹啉-2-甲酰胺(Ⅰ-27)的合成
参照实施例13中步骤3所述的方法,得到白色固体73mg,产率51.25%。1H NMR(400MHz,DMSO-d6)δ(ppm):8.65(d,J=8.5Hz,1H),8.54(d,J=8.5Hz,1H),8.24(d,J=2.4Hz,1H),8.18(dd,J=8.8,5.8Hz,2H),7.96-7.92(m,2H),7.88(dd,J=9.1,2.4Hz,1H),7.86-7.82(m,2H),5.33(s,2H),3.83-3.76(m,1H),2.07-1.93(m,1H),1.89(d,J=11.7Hz,4H),1.62-1.53(m,2H),1.38-1.33(m,2H).;MS(ESI)m/z:calculated for C25H23BrClN5O2[M+H]+:540.07,found:540.8.。
实施例38
反-6-氯-N-(4-(((5-(4-氯-3-氟苯基)-1,3,4-噁二唑-2-基)甲基)氨基)环己基)喹啉-2-甲酰胺(Ⅰ-28)的合成
参照实施例13中步骤3所述的方法,得到白色固体22mg,产率21.66%。1H NMR(400MHz,DMSO-d6)δ(ppm):8.68(d,J=8.5Hz,1H),8.54(d,J=8.6Hz,1H),8.25(d,J=2.4Hz,1H),8.18(dd,J=8.8,4.1Hz,2H),8.04-7.99(m,1H),7.92 -7.86(m,3H),5.34(s,2H),3.80(d,J=9.0Hz,1H),2.06-1.95(m,1H),1.88(d,J=11.5Hz,4H),1.58(q,J=11.8Hz,2H),1.36(t,J=11.2Hz,2H);MS(ESI)m/z:calculated for C25H22Cl2FN5O2[M+H]+:514.11,found:514.0.。
实施例39
中间体2-(5-氯苯并呋喃-2-基)-5-(哌啶-4-基)-1,3,4-噁二唑的合成
步骤1:5-氯苯并呋喃-2-碳酰肼的合成
参照实施例3中步骤1所述的方法,得到白色固体248mg,产率95.15%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.13(s,1H),7.87(d,J=2.2Hz,1H),7.69(d,J=8.8Hz,1H),7.52-7.43(m,2H),4.63(s,2H).
步骤2:4-(2-(5-氯苯并呋喃-2-羰基)肼-1-羰基)哌啶-1-羧酸叔丁酯的合成
参照实施例1中步骤3所述的方法,得到淡黄色固体180mg,产率95.60%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.68(s,1H),10.03(s,1H),7.92(d,J=2.2Hz,1H),7.74(d,J=8.8Hz,1H),7.64(d,J=0.9Hz,1H),7.52(dd,J=8.9,2.2Hz,1H),3.97(d,J=13.1Hz,2H),2.77(d,J=19.6Hz,2H),2.49-2.39(m,1H),1.73(d,J=12.8Hz,2H),1.54–1.43(m,2H),1.41(s,9H).
步骤3:2-(5-氯苯并呋喃-2-基)-5-(哌啶-4-基)-1,3,4-噁二唑的合成
参照实施例2所述的方法,得到淡黄色固体102mg,产率78.71%。MS(ESI)m/z:calculatedfor C15H14ClN3O2[M+H]+:304.08,found:304.43.。
实施例39
1-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)哌啶-1-基)-2-(4-氯苯氧基)乙烷-1-酮(II-1)的合成
参照实施例1中步骤3所述的方法,纯化得到白色固体44 mg,产率27.74%。1H NMR(300MHz,DMSO-d6)δ(ppm):7.91(d,J=2.2Hz,1H),7.85(d,J=8.9Hz,1H),7.78(s,1H),7.55(dd,J=8.9,2.2Hz,1H),7.37–7.30(m,2H),7.00–6.93(m,2H),4.90(d,J=4.0Hz,2H),4.26(d,J=13.3Hz,1H),3.88(d,J=13.8Hz,1H),3.46(d,J=6.7Hz,1H),3.27(d,J=12.2Hz,1H),2.97(t,J=12.2Hz,1H),2.13(s,2H),1.87(q,J=10.8Hz,1H),1.67(q,J=10.0Hz,1H).;MS(ESI)m/z:calculated for C23H19Cl2N3O4[M+H]+:472.08,found:472.4.。
实施例40
反-N-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)环己基)-2-(4-氯苯氧基)乙酰胺(II-2)的合成
步骤1:反-4-(2-(5-氯苯并呋喃-2-羰基)肼-1-羰基)环己基)氨基甲酸叔丁酯的合成
参照实施例1中步骤3所述的方法,得到淡黄色固体160mg,产率80.53%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.65(s,1H),9.92(s,1H),7.92(d,J=2.2Hz,1H),7.74(d,J=8.9Hz,1H),7.63(d,J=0.9Hz,1H),7.51(dd,J=8.9,2.2Hz,1H),6.77(d,J=8.0Hz,1H),3.18(s,1H),2.16(t,J=12.1Hz,1H),1.81(t,J=12.4Hz,4H),1.38(d,J=2.7Hz,9H),1.21(dq,J=24.2,12.2Hz,4H).
步骤2:反-4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)环己-1-胺的合成
参照实施例2所述的方法,得到淡黄色固体99mg,产率72.62%。MS(ESI)m/z:calculated for C15H14ClN3O2[M+H]+:318.09,found:318.06
步骤3:反-N-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)环己基)-2-(4-氯苯氧基)乙酰胺(Ⅲ-2)的合成
参照实施例1中步骤3所述的方法,得到乳白色固体57mg,产率37.62%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.07(d,J=8.2Hz,1H),7.90(s,1H),7.84(d,J=8.9Hz,1H),7.77(d,J=6.9Hz,1H),7.54(d,J=9.0Hz,1H),7.40-7.29(m,2H),6.98(dt,J=14.0,6.7Hz,2H),4.49(s,2H),3.72(d,J=9.2Hz,1H),3.11-2.93(m,1H),2.19(d,J=13.5Hz,2H),1.91(d,J=12.3Hz,2H),1.67(d,J=12.4Hz,2H),1.47(q,J=12.6Hz,2H);MS(ESI)m/z:calculated for C24H21Cl2N3O4[M+H]+:486.09,found:486.4.。
实施例41
反-N-((4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)环己基)甲基)-2-(4-氯苯氧基)乙酰胺(II-3)的合成
步骤1:反-((4-(2-(5-氯苯并呋喃-2-羰基)肼-1-羰基)环己基)甲基)氨基甲酸叔丁酯的合成
参照实施例1中步骤3所述的方法,得到淡黄色固体364mg,产率85.20%。1H NMR(300MHz,DMSO-d6)δ(ppm):10.63(s,1H),9.91(s,1H),7.92(d,J=2.2Hz,1H),7.74(d,J=8.9Hz,1H),7.63(d,J=0.9Hz,1H),7.51(dd,J=8.9,2.3Hz,1H),6.83(t,J=5.9Hz,1H),2.92-2.67(m,3H),2.19(t,J=12.0Hz,1H),1.86 -1.67(m,4H),1.38(s,9H),1.32(d,J=10.5Hz,2H),0.98-0.83(m,2H).
步骤2:反-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)环己基)甲胺的合成
参照实施例2所述的方法,得到淡黄色固体235mg,产率88.77%。MS(ESI)m/z:calculated for C15H14ClN3O2[M+H]+:332.11,found:332.92.
步骤3:反-N-((4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)环己基)甲基)-2-(4-氯苯氧基)乙酰胺(II-3)的合成
参照实施例1中步骤3所述的方法,得到白色固体108mg,产率30.47%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.16(t,J=6.0Hz,1H),7.90(d,J=2.2Hz,1H),7.84(d,J=8.9Hz,1H),7.76(d,J=1.0Hz,1H),7.54(dd,J=8.9,2.2Hz,1H),7.39-7.33(m,2H),7.03-6.97(m,2H),4.52(s,2H),3.04(t,J=6.4Hz,2H),3.01-2.92(m,1H),2.15(d,J=11.7Hz,2H),1.79(d,J=12.7Hz,2H),1.54(dd,J=13.5,10.1Hz,3H),1.07(d,J=12.3Hz,2H);MS(ESI)m/z:calculated for C25H23Cl2N3O4[M+H]+:500.11,found:500.4.。
实施例42
反-N-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)环己基)-5-(4-氯苯基)-1,3,4-噁二唑-2-甲酰胺(II-4)的合成
/>
参照实施例1中步骤3所述的方法,得到白色固体33mg,产率35.06%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.45(t,J=6.1Hz,1H),8.15-8.08(m,2H),7.90(d,J=2.2Hz,1H),7.84(d,J=8.8Hz,1H),7.75(d,J=5.0Hz,2H),7.73 -7.70(m,1H),7.54(dd,J=8.9,2.2Hz,1H),3.21(d,J=6.5Hz,2H),3.04(s,1H),2.19(d,J=12.7Hz,2H),1.90(d,J=13.0Hz,2H),1.66(d,J=18.3Hz,1H),1.52(d,J=12.9Hz,2H);MS(ESI)m/z:calculatedfor C26H21Cl2N5O4[M+H]+:538.10,found:538.5.。
实施例43
反-N-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-噁二唑-2-基)环己基)-3-(4-氯苯基)-1,2,4-噁二唑-5-甲酰胺(II-5)的合成
参照实施例1中步骤3所述的方法,得到白色固体30mg,产率23.11%。1H NMR(300MHz,DMSO-d6)δ(ppm):9.56(t,J=6.1Hz,1H),8.13-8.06(m,2H),7.90(d,J=2.2Hz,1H),7.84(d,J=8.9Hz,1H),7.76(d,J=0.9Hz,1H),7.74-7.65(m,2H),7.54(dd,J=8.9,2.2Hz,1H),3.22(t,J=6.5Hz,2H),3.04(s,1H),2.19(d,J=12.7Hz,2H),1.90(d,J=13.0Hz,2H),1.70(s,1H),1.55(t,J=12.9Hz,2H),1.21-1.13(m,2H);MS(ESI)m/z:calculated for C26H21Cl2N5O4[M+H]+:538.10,found:538.4.。
实施例44
中间体4-(5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)环己烷-1-胺的合成
步骤1:5-氯-1H-吲哚-2-碳酰肼的合成
参照实施例39步骤1中所述的方法,得黄白色固体308mg,产率:91.33%。1H NMR(400MHz,DMSO-d6)δ11.90–11.77(m,1H),9.88(s,1H),7.67(d,J=2.0Hz,1H),7.43(d,J=8.7Hz,1H),7.17(dd,J=8.7,2.1Hz,1H),7.07(d,J=2.0Hz,1H).
步骤2:(4-(2-(5-氯-1H-吲哚-2-羰基)肼-1-羰基)环己基)氨基甲酸叔丁酯的合成
参照实施例39步骤2中所述的方法,得白色固体408mg,产率99.74%。1H NMR(300MHz,DMSO-d6)δ11.89(d,J=2.1Hz,1H),10.42(s,1H),9.86(s,1H),7.73(d,J=2.1Hz,1H),7.45(d,J=8.7Hz,1H),7.25–7.15(m,2H),6.77(d,J=8.1Hz,1H),3.10(m,1H)2.17(t,J=11.9Hz,1H),1.80(d,J=12.2Hz,4H),1.38(s,9H),1.38(m,2H),1.20(m,2H).
步骤3:4-(5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)环己烷-1-胺的合成
参照实施例39步骤3中所述的方法,得黄白色固体205mg,产率86%。1H NMR(500MHz,Chloroform-d)δ9.61(s,1H),7.75(s,1H),7.63(s,1H),7.38(s,1H),7.06(s,1H),5.69(s,1H),3.81(s,1H),3.24(s,1H),2.96(s,1H),1.80–1.69(m,4H),1.70–1.60(m,4H).。
实施例45
N-(4-(5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)环己基)-2-(4-氯苯氧基)乙酰胺(Ⅱ-6)的合成
参照实施例1中步骤3所述的方法,得到白色固体23mg,产率22.53%。1H NMR(300MHz,DMSO-d6)δ12.46(s,1H),8.07(d,J=8.0Hz,1H),7.74(d,J=2.0Hz,1H),7.48(d,J=8.8Hz,1H),7.37(d,J=2.3Hz,1H),7.35(d,J=2.3Hz,1H),7.26(dd,J=8.7,2.1Hz,1H),7.15(s,1H),7.00(d,J=2.3Hz,1H),6.98(d,J=2.3Hz,1H),4.49(s,2H),3.71(ddd,J=11.6,7.6,3.8Hz,1H),3.00(tt,J=11.6,3.5Hz,1H),2.20(d,J=11.7Hz,2H),1.91(dd,J=12.7,3.8Hz,2H),1.67(qd,J=13.0,3.1Hz,2H),1.57–1.37(m,2H).MS(ESI)m/z:calculated for C24H22Cl2N4O3[M+H]+:485.11,found:485.4.。
实施例46
(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)(5-(4-氯苯基)-1,3,4恶二唑-1-基)甲酮(Ⅱ-7)的合成
参照实施例1中步骤3所述的方法,得到白色固体54mg,产率40.00%。1H NMR(300MHz,DMSO-d6)δ8.10(d,J=2.0Hz,1H),8.07(d,J=2.0Hz,1H),7.91(d,J=2.2Hz,1H),7.85(d,J=8.9Hz,1H),7.79(d,J=0.9Hz,1H),7.74(d,J=2.0Hz,1H),7.72(d,J=2.0Hz,1H),7.55(dd,J=8.9,2.2Hz,1H),4.50(dd,J=43.3,13.4Hz,2H),3.69–3.49(m,2H),3.32–3.25(m,1H),2.31–2.16(m,2H),2.05–1.79(m,2H).MS(ESI)m/z:calculated forC24H17Cl2N5O4[M+H]+510.07,found:510.33.。
实施例47
中间体2-(5-氯-1H-吲哚-2-基)-5-(哌啶-4-基)-1,3,4-恶二唑的合成
步骤1:4-(2-(5-氯-1H-吲哚-2-羰基)肼-1-羰基)哌啶-1-甲酸叔丁酯的合成
原料为1-(叔丁氧羰基)哌啶-4-羧酸,参照实施例1中步骤3的合成得黄白色固体473mg,产率为99.72%。1H NMR(300MHz,DMSO-d6)δ11.90(d,J=2.1Hz,1H),10.46(s,1H),9.97(s,1H),7.74(d,J=2.0Hz,1H),7.45(d,J=8.7Hz,1H),7.26–7.16(m,2H),3.97(d,J=13.1Hz,2H),2.71(s,1H),1.81–1.69(m,2H),1.50(td,J=12.3,4.1Hz,2H),1.41(s,9H),1.23(t,J=8.2Hz,2H).
步骤2:2-(5-氯-1H-吲哚-2-基)-5-(哌啶-4-基)-1,3,4-恶二唑的合成
参照实施例39中步骤3的合成得棕黄色固体156mg,产率91.92%。1H NMR(400MHz,DMSO-d6)δ11.93(s,1H),7.74(d,J=2.1Hz,1H),7.45(d,J=8.7Hz,1H),7.23–7.18(m,2H),3.10(s,4H),2.85(s,1H),2.56(s,1H),1.88(d,J=17.2Hz,4H).。
实施例48
(4-(5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)(5-(4-氯苯基)-1,3,4恶二唑-1-基)甲酮(Ⅱ-8)的合成
参照实施例1中步骤3所述的方法,得到白色固体53mg,产率36.63%。1H NMR(500MHz,Chloroform-d)δ9.61(s,1H),8.14–8.08(m,3H),7.62(s,1H),7.56(s,1H),7.48–7.39(m,4H),7.17(s,1H),4.50(dd,J=43.3,13.4Hz,2H),3.69–3.49(m,2H),3.32–3.25(m,1H),2.31–2.16(m,2H),2.05–1.79(m,2H).MS(ESI)m/z:calculated for C24H18Cl2N6O3[M+H]+509.08,found:509.35.。
实施例49
中间体(1r,4r)-4-((5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)甲基)环己烷-1-胺的合成
步骤1:叔丁基((1r,4r)-4-(2-(2-(5-氯-1H-吲哚-2-羰基)肼基)-2-氧乙基)环己基)氨基甲酸酯的合成
原料为实施例44步骤1合成的5-氯-1H-吲哚-2-碳酰肼、(1r,4r)-4-((叔丁氧羰基)氨基)环己烷-1-甲酸。参照实施例1中步骤3的合成,得黄白色固体374mg,产率为78.72%。1H NMR(300MHz,DMSO-d6)δ11.94(s,1H),10.40(s,1H),9.87(s,1H),7.74(d,J=2.0Hz,1H),7.44(d,J=8.7Hz,1H),7.29–7.15(m,2H),6.70(d,J=8.1Hz,1H),3.18(d,J=10.4Hz,1H),2.07(d,J=6.9Hz,2H),1.78(s,4H),1.62(m,1H),1.38(s,9H),1.19(d,J=12.6Hz,1H),1.16–0.92(m,3H).
步骤2:(1r,4r)-4-((5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)甲基)环己烷-1-胺的合成
参照实施例39中步骤3的合成得棕黄色固体48mg,产率30.27%。MS(ESI)m/z:calculated for C17H19ClN4O[M+H]+:330.82,found:330.83。
实施例50
N-((1r,4r)-4-((5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)甲基)环己基)-2-(4-氯苯氧基)乙酰胺(Ⅱ-9)的合成
参照实施例1中步骤3所述的方法,得到白色固体27mg,产率74.32%。1H NMR(300MHz,DMSO-d6)δ12.45(s,1H),7.95(d,J=8.1Hz,1H),7.74(d,J=2.0Hz,1H),7.49(d,J=8.7Hz,1H),7.40–7.28(m,2H),7.26(dd,J=8.8,2.1Hz,1H),7.15(s,1H),7.03–6.91(m,2H),4.45(s,2H),3.61(d,J=8.3Hz,1H),2.87(d,J=6.4Hz,2H),1.80(d,J=8.3Hz,5H),1.40–1.23(m,2H),1.28–1.08(m,2H).MS(ESI)m/z:calculated for C25H24Cl2N4O3[M+H]+:499.12,found:499.39。
实施例51
中间体(1r,4r)-4-((5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)甲基)环己烷-1-胺的合成
步骤1:叔丁基((1r,4r)-4-(2-(2-(5-氯苯并呋喃-2-羰基)肼基)-2-氧乙基)环己基)氨基甲酸酯的合成
原料为实施例39步骤1合成的5-氯苯并呋喃-2-碳酰肼、(1r,4r)-4-((叔丁氧羰基)氨基)环己烷-1-甲酸。参照实施例1中步骤3的合成,得白色固体582mg,产率为82.21%。1HNMR(300MHz,DMSO-d6)δ10.40(s,1H),9.87(s,1H),7.74(d,J=2.0Hz,1H),7.44(d,J=8.7Hz,1H),7.29–7.15(m,2H),6.70(d,J=8.1Hz,1H),3.18(d,J=10.4Hz,1H),2.07(d,J=6.9Hz,2H),1.78(s,4H),1.62(m,1H),1.38(s,9H),1.19(d,J=12.6Hz,1H),1.16–0.92(m,3H).
步骤2:(1r,4r)-4-((5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)甲基)环己烷-1-胺的合成。
参照实施例39中步骤3的合成得棕黄色固体92mg,产率73%。1H NMR(300MHz,DMSO-d6)δ7.93–7.80(m,2H),7.76(s,1H),7.54(dd,J=8.8,2.2Hz,1H),2.87(d,J=6.4Hz,2H),1.75(s,5H),1.10(d,J=18.2Hz,5H).。
实施例52
N-((1r,4r)-4-((5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)甲基)环己基)-2-(4-氯苯氧基)乙酰胺(Ⅱ-10)的合成
参照实施例1中步骤3所述的方法,得到白色固体53mg,产率84.32%。1H NMR(400MHz,DMSO-d6)δ7.93(d,J=8.1Hz,1H),7.89(d,J=2.2Hz,1H),7.84(d,J=8.8Hz,1H),7.75(d,J=0.9Hz,1H),7.54(dd,J=8.9,2.2Hz,1H),7.41–7.29(m,2H),7.04–6.92(m,2H),3.61(dtt,J=11.5,7.8,3.9Hz,1H),2.90(d,J=6.5Hz,2H),1.78(td,J=9.6,8.7,4.4Hz,5H),1.38–1.09(m,4H).MS(ESI)m/z:calculated for C25H23Cl2N3O4[M+H]+:500.11,found:500.39。
实施例53
中间体2-(4-氯苯氧基)-N-((1r,4r)-4-(肼羰基)环己基)乙酰胺的合成
步骤1:(1r,4r)-4-(2-(4-氯苯氧基)乙酰胺基)环己烷-1-甲酸甲酯的合成
原料为(1r,4r)-4-氨基环己烷-1-甲酸甲酯,参照实施例1中步骤3所述的方法。得白色固体335mg,产率72.24%。1H NMR(300MHz,DMSO-d6)δ7.97(d,J=7.8Hz,1H),7.40–7.29(m,2H),7.03–6.92(m,2H),4.45(s,2H),3.59(s,3H),2.25(ddt,J=11.6,7.1,3.5Hz,1H),2.00–1.85(m,2H),1.85–1.71(m,2H),1.49–1.13(m,5H).
步骤2:2-(4-氯苯氧基)-N-((1r,4r)-4-(肼羰基)环己基)乙酰胺的合成
参照实施例1中步骤3所述的方法,得到白色固体273mg,产率72.47%。1H NMR(300MHz,DMSO-d6)δ8.93(s,1H),7.95(d,J=8.1Hz,1H),7.44–7.26(m,2H),7.05–6.89(m,2H),4.45(s,2H),4.14(s,2H),3.68–3.48(m,1H),2.00(tt,J=12.0,3.5Hz,1H),1.86–1.60(m,4H),1.54–1.34(m,2H),1.34–1.13(m,2H).。
实施例54
2-(4-氯苯氧基)-N-((1r,4r)-4-(5-(6-氯喹啉-2-基)-1,3,4-恶二唑-2-基)环己基)乙酰胺(Ⅱ-11)的合成
步骤1:2-(4-氯苯氧基)-N-((1r,4r)-4-(2-(6-氯喹啉-2-羰基)肼-1-羰基)环己基)乙酰胺的合成
原料为实施例53步骤2的2-(4-氯苯氧基)-N-((1r,4r)-4-(肼羰基)环己基)乙酰胺、实施例29步骤2的6-氯喹啉-2-羧酸。参照实施例1中步骤3所述的方法。得白色固体261mg,产率72%。1H NMR(300MHz,DMSO-d6)δ10.60(s,1H),10.06(s,1H),8.58(d,J=8.6Hz,1H),8.28(d,J=2.4Hz,1H),8.22–8.09(m,2H),8.06–7.86(m,2H),7.43–7.25(m,2H),7.07–6.88(m,2H),4.47(s,2H),3.72–3.53(m,1H),2.26(t,J=11.3Hz,1H),1.85(d,J=11.2Hz,4H),1.59–1.18(m,4H).
步骤2:2-(4-氯苯氧基)-N-((1r,4r)-4-(5-(6-氯喹啉-2-基)-1,3,4-恶二唑-2-基)环己基)乙酰胺的合成(Ⅱ-11)
参照实施例39中步骤3的合成得白色固体92mg,产率20.00%。1H NMR(400MHz,DMSO-d6)δ8.61(d,J=8.7Hz,1H),8.38–8.26(m,2H),8.19(d,J=9.0Hz,1H),8.05(d,J=8.0Hz,1H),7.90(dd,J=9.0,2.4Hz,1H),7.44–7.30(m,2H),7.08–6.93(m,2H),4.49(s,2H),3.74(dtd,J=11.9,8.0,4.0Hz,1H),3.09(tt,J=12.0,3.7Hz,1H),2.28–2.17(m,2H),1.93(dd,J=13.2,3.7Hz,2H),1.71(qd,J=13.0,3.3Hz,2H),1.49(qd,J=12.8,3.6Hz,2H).MS(ESI)m/z:calculated for C25H22Cl2N4O3[M+H]+:497.11,found:497.39.。
实施例55
中间体6-氯喹啉-2-羧酰胺的合成
步骤1:6-溴喹啉-2-甲酰胺的合成
将6-溴喹啉-2-羧酸(1.49g,5.90mmol)溶于无水乙腈(20ml)中,在冰浴条件下加入草酰氯(900μl,10.63mmol),再加入5滴N,N-二甲基甲酰胺,反应3h。将反应混合物加入在冰浴条件下制得的氨水(1.14ml,29.57mmol):乙腈=1:10的溶液中,20min后反应完全。抽滤,烘干,得淡黄色固体1.16g,产率72.64%。1H NMR(300MHz,DMSO-d6)δ8.53(d,J=8.5Hz,1H),8.40(d,J=2.2Hz,1H),8.33(s,1H),8.19(d,J=8.6Hz,1H),8.05(d,J=9.0Hz,1H),7.98(dd,J=9.0,2.2Hz,1H),7.84(s,1H).
步骤2:6-溴喹啉-2-腈的合成
将6-溴喹啉-2-甲酰胺(500mg,1.99mmol)溶于10mlN,N-二甲基甲酰胺中,随后加入五氯化磷(1.24g,5.97mmol),于50℃下反应1h。加水抽滤。滤饼用二氯甲烷溶解,将滤液浓缩,残留物通过硅胶柱层析(石油醚/乙酸乙酯=20/1)纯化得到白色固体,产率33.83%。1HNMR(300MHz,DMSO-d6)δ8.64(d,J=8.5Hz,1H),8.52–8.43(m,1H),8.16–8.01(m,3H).
步骤3:6-溴喹啉-2-羧酰胺的合成
将6-溴喹啉-2-腈(220mg,943.93μmol)加到10ml无水甲醇中,随后加入甲醇钠(51mg,943.93μmol),于40℃下反应30min。加入NH4Cl(151.47mg,2.83mmol),反应3h,NH3·H2O调节PH~8。硅藻土抽滤,用少量甲醇洗涤。将滤液浓缩,残留物用二氯甲烷打浆析出固体,抽滤得白色固体,产率86.51%。1H NMR(300MHz,DMSO-d6)δ8.74(d,J=8.7Hz,1H),8.64–8.45(m,2H),8.12(d,J=9.0Hz,1H),8.08(dd,J=9.1,2.0Hz,1H),7.73(s,1H),6.26(s,2H).。
实施例56
2-(4-氯苯氧基)-N-((1r,4r)-4-(5-(6-溴喹啉-2-基)-4H-1,2,4-三唑-3-基)环己基)乙酰胺(Ⅱ-12)的合成
原料为实施例55步骤3的6-溴喹啉-2-羧酰胺、实施例53步骤2的2-(4-氯苯氧基)-N-((1r,4r)-4-(肼羰基)环己基)乙酰胺。
将6-溴喹啉-2-羧酰胺(105mg,322.29μmol)、2-(4-氯苯氧基)-N-((1r,4r)-4-(肼羰基)环己基)乙酰胺(78mg,322.29μmol)投入封管,用N,N-二甲基甲酰胺溶解,于130℃下反应5h。用乙酸乙酯萃取,无水硫酸钠干燥,过滤,滤液经减压浓缩,残留物通过硅胶柱层析纯化得到白色固体17mg,产率9.75%。1H NMR(300MHz,DMSO-d6)δ14.35(d,J=169.1Hz,1H),8.48(dd,J=30.8,8.6Hz,1H),8.36(d,J=20.6Hz,1H),8.29–8.18(m,1H),8.07(d,J=9.3Hz,1H),8.02(s,1H),7.94(dd,J=16.1,8.9Hz,1H),7.35(dd,J=7.7,5.4Hz,2H),7.09–6.91(m,2H),4.47(d,J=11.2Hz,2H),3.71(s,1H),2.95–2.65(m,1H),2.11(d,J=12.7Hz,2H),1.90(d,J=12.0Hz,2H),1.56(dq,J=61.1,12.9,12.1Hz,4H).MS(ESI)m/z:calculated for C25H23BrClN5O2[M+H]+:541.85,found:542.07.。
实施例57
(5-(4-氯-3-氟苯基)-1,3,4-恶二唑-2-基)(4-(5-(5-氯苯并呋喃-2-基)-1,3,44-恶二唑-1-基)哌啶-1-基)甲酮(Ⅱ-13)的合成
参照实施例1中步骤3所述的方法,得到白色固体72mg,产率87.2%。1H NMR(400MHz,DMSO-d6)δ7.91(d,J=2.3Hz,1H),7.90–7.87(m,1H),7.85(d,J=8.8Hz,1H),7.82–7.70(m,3H),7.55(dd,J=8.8,2.2Hz,1H),4.26(d,J=13.3Hz,1H),4.09(d,J=13.6Hz,1H),3.59–3.39(m,2H),3.11(t,J=11.4Hz,1H),2.27–2.13(m,2H),1.93(t,J=10.9Hz,1H),1.78(q,J=10.1Hz,1H).MS(ESI)m/z:calculated for C24H16Cl2FN5O4,[M+H]+:527.06,found:527.35。
实施例58
(4-(5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)(5-(4-氯-3-氟苯基)-1,3,44-恶二唑-1-基)甲酮(Ⅱ-14)的合成
原料为实施例47步骤2的2-(5-氯-1H-吲哚-2-基)-5-(哌啶-4-基)-1,3,4-恶二唑、实施例10步骤1的5-(4-氯-3-氟苯基)-1,3,4-恶二唑-2-羧酸
参照实施例1中步骤3所述的方法,得到白色固体27mg,产率72.17%。1H NMR(400MHz,DMSO-d6)δ12.46(d,J=2.1Hz,1H),8.08(dd,J=9.5,1.9Hz,1H),7.98–7.86(m,2H),7.75(d,J=2.0Hz,1H),7.49(d,J=8.7Hz,1H),7.27(dd,J=8.8,2.0Hz,1H),7.22–7.16(m,1H),4.48(dd,J=40.9,13.6Hz,2H),3.69–3.47(m,2H),2.31–2.15(m,2H),2.04–1.82(m,2H),0.86(t,J=6.7Hz,1H).MS(ESI)m/z:calculated for C24H17Cl2FN6O3[M+H]+:527.07,found:527.31。
实施例59
中间体5-氯苯呋喃-2-羧酰胺的合成
步骤1:5-氯苯呋喃-2-甲酰胺的合成
参照实施例55步骤1所述的方法,得白色固体2.12g,产率87.24%。1H NMR(300MHz,Chloroform-d)δ9.12(s,2H),7.69(dd,J=1.9,0.9Hz,1H),7.38(dt,J=8.8,0.8Hz,1H),7.29(dd,J=8.8,2.0Hz,1H),7.18(dd,J=2.1,0.9Hz,1H).
步骤2:5-氯苯呋喃-2-腈的合成
参照实施例55步骤2所述的方法,得白色固体779mg,产率77.41%。1H NMR(300MHz,DMSO-d6)δ8.09(d,J=1.0Hz,1H),7.96(dd,J=2.2,0.6Hz,1H),7.81(dt,J=9.0,0.8Hz,1H),7.64(dd,J=8.9,2.2Hz,1H).
步骤3:5-氯苯呋喃-2-羧酰胺的合成
参照实施例55步骤3所述的方法,得白色固体257mg,产率98.73%。1H NMR(300MHz,DMSO-d6)δ8.30(s,1H),8.25(s,1H),8.17–8.12(m,2H),8.07(d,J=2.2Hz,1H),7.78(d,J=8.9Hz,1H),7.62(dd,J=8.9,2.2Hz,1H).。
实施例60
N-((1r,4r)-4-(5-(5-氯苯并呋喃-2-基)-4H-1,2,4-三唑-3-基)环己基)-2-(4-氯苯氧基)乙酰胺(Ⅱ-15)的合成
参照实施例56,得白色固体21mg,产率30.20%。1H NMR(300MHz,DMSO-d6)δ14.18(s,1H),8.07(d,J=8.1Hz,1H),7.78(d,J=2.2Hz,1H),7.71(d,J=8.8Hz,1H),7.43–7.31(m,3H),7.06–6.94(m,2H),4.47(s,2H),2.88–2.72(m,1H),2.07(d,J=12.4Hz,2H),1.93–1.80(m,2H),1.61(dt,J=13.7,11.0Hz,2H),1.52–1.35(m,2H).MS(ESI)m/z:calculatedfor C24H22Cl2N4O3[M+H]+:485.11,found:485.11.。
实施例61
(4-(5-(5-氯-1H-吲哚-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)(3-(4-氯苯基)-1,2,4-恶二唑-5-基)甲酮(Ⅱ-16)的合成
原料为实施例47步骤2的2-(5-氯-1H-吲哚-2-基)-5-(哌啶-4-基)-1,3,4-恶二唑、实施例47步骤3的3-(4-氯苯基)-1,2,4-恶二唑-5-羧酸
参照实施例1中步骤3所述的方法,得到白色固体22mg,产率69.84%。1H NMR(400MHz,DMSO-d6)δ12.67–12.34(m,1H),8.14–8.04(m,2H),7.75(d,J=2.1Hz,1H),7.73–7.66(m,2H),7.49(d,J=8.7Hz,1H),7.26(dt,J=8.6,2.3Hz,1H),7.18(dd,J=2.2,0.9Hz,1H),4.42(d,J=13.3Hz,1H),4.22(d,J=13.6Hz,1H),3.56(ddt,J=14.7,10.7,5.4Hz,2H),2.37–2.16(m,2H),1.98–1.83(m,2H),0.86(t,J=6.2Hz,1H).MS(ESI)m/z:calculatedfor C24H18Cl2N6O3[M+H]+:509.08,found:509.53.。
实施例62
中间体2-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)-2-氧代乙酰酰肼的合成
步骤1:2-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)-2-氧代乙酸乙酯的合成
原料为实施例39步骤3的2-(5-氯苯并呋喃-2-基)-5-(哌啶-4-基)-1,3,4-恶二唑、草酰氯单乙酯。参照实施例3步骤2所述方法,得白色固体217mg,产率92.7%。1H NMR(300MHz,Chloroform-d)δ7.70(dd,J=2.1,0.6Hz,1H),7.57(dt,J=8.8,0.7Hz,1H),7.47(d,J=0.9Hz,1H),7.43(dd,J=8.9,2.1Hz,1H),4.48–4.32(m,3H),3.85(dtd,J=13.9,4.4,1.3Hz,1H),3.38(dddd,J=13.8,10.4,5.4,3.6Hz,2H),3.18(ddd,J=13.9,10.7,3.3Hz,1H),2.36–2.20(m,2H),2.06(ddtd,J=24.3,14.4,10.5,4.1Hz,2H),1.40(t,J=7.1Hz,3H).
步骤2:2-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)-2-氧代乙酰酰肼的合成。
参照实施例3步骤1所述方法,于95℃反应。得白色固体154mg,产率72.17%。MS(ESI)m/z:calculated for C17H16ClN5O4[M+H]+:390.09,found:390.21。
实施例63
中间体(1s,3s)-3-(三氟甲氧基)环丁烷-1-甲酸的合成
步骤1:苄基(1s,3s)-3-羟基环丁烷-1-甲酸酯的合成
用10ml无水甲醇将3-氧代环丁烷-1-甲酸苄酯(436mg,2.13mmol)溶解,在-30℃下,逐份添加NaBH4(85mg 2.24mmol),反应3h。添加NH4Cl饱和溶液,将滤液浓缩除去挥发物。用EA萃取,收集有机相,浓缩得无色透明液体407mg,产率92.33%。1H NMR(300MHz,Chloroform-d)δ7.45–7.33(m,5H),4.27–4.14(m,1H),2.75–2.55(m,3H),2.48–2.32(s,1H),2.26–2.15(m,2H).
步骤2:苄基(1s,3s)-3-(三氟甲氧基)环丁烷-1-甲酸酯的合成
于包裹由锡纸并冷却在-35℃的三颈烧瓶中,依次添加AgOTf(I)(7.40g,28.80mmol)、Selectfluor(5.10g,14.40mmol)、KF(2.23g,38.40mmol)、以及溶于无水乙酸乙酯的苄基(1s,3s)-3-羟基环丁烷-1-甲酸酯(1.98g,9.60mmol),N2保护下,放置30min。后依次滴加2-氟吡啶(2.54ml,28.80mmol)、TMSCF3(4.26ml,28.80mmol)保证内部温度低于-30℃。随后移入室温隔夜反应。将反应液经硅藻土过滤,EA洗涤,浓缩溶液,残留物经硅胶柱层析(PE/EA=200/1)洗脱,得无色透明液体1.30g,产率49.38%。1H NMR(300MHz,Chloroform-d)δ7.38(d,J=14.1Hz,5H),5.17(d,J=2.1Hz,2H),4.59(t,J=7.6Hz,1H),2.85–2.48(m,5H).19F NMR(282MHz,Chloroform-d)δ-59.55.MS(ESI)m/z:calculated forC13H13F3O3[M+Na]+:297.24,found:297.11
步骤3:(1s,3s)-3-(三氟甲氧基)环丁烷-1-甲酸的合成
苄基(1s,3s)-3-(三氟甲氧基)环丁烷-1-甲酸酯(1.21g,4.40mmol)用THF溶解,加入NaOH(880mg,22mmol)隔夜反应。将反应也浓缩,残留物用二氯甲烷/1molHCl水溶液萃取,收集有机相,旋干得无色液体793mg,产率97.94%。1H NMR(400MHz,DMSO-d6)δ12.63(s,1H),4.47(p,J=7.1Hz,1H),3.95(s,2H),3.81 3.70(m,1H),2.75(tdt,J=9.0,5.7,2.4Hz,2H),2.15-2.03(m,2H).。
实施例64
(4-(5-(5-(氯代呋喃-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)(5-((1s,3s)-3-(三氟甲氧基)环丁基)-1,3,4恶二唑-1-基)甲酮(Ⅱ-17)的合成
步骤1:(1s,3s)-N'-(2-(4-(5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)-2-氧代乙酰基)-3-(三氟甲氧基)环丁烷-1-甲酰肼的合成
参照实施例1中步骤3所述的方法,得到白色固体157mg,产率73.21%.1H NMR(300MHz,DMSO-d6)δ10.16(s,2H),7.91(d,J=2.2Hz,1H),7.84(d,J=8.9Hz,1H),7.78(s,1H),7.54(dd,J=8.9,2.2Hz,1H),4.81(p,J=7.6Hz,1H),4.23(d,J=13.0Hz,2H),4.13–3.95(m,2H),3.06(t,J=12.0Hz,2H),2.78–2.69(m,1H),2.30(q,J=9.6Hz,2H),2.15(d,J=13.1Hz,2H),1.83(dq,J=25.7,11.7,10.7Hz,3H).
步骤2:(4-(5-(5-(氯代呋喃-2-基)-1,3,4-恶二唑-2-基)哌啶-1-基)(5-((1s,3s)-3-(三氟甲氧基)环丁基)-1,3,4恶二唑-1-基)甲酮的合成
参照实施例39中步骤3的合成得白色固体25mg,产率27.13%。1H NMR(400MHz,Chloroform-d)δ7.70(d,J=2.1Hz,1H),7.57(d,J=8.8Hz,1H),7.48(s,1H),7.43(dd,J=8.8,2.1Hz,1H),5.00–4.91(m,1H),4.76(p,J=7.6Hz,1H),4.62(dt,J=13.8,4.4Hz,1H),3.71(ddd,J=13.9,10.7,3.1Hz,1H),3.44(tdd,J=10.1,7.5,5.2Hz,2H),3.34(ddd,J=13.8,10.7,3.2Hz,1H),2.94(dddt,J=9.9,7.4,5.3,2.6Hz,2H),2.80(tdd,J=10.3,8.0,2.8Hz,2H),2.34(dt,J=12.6,3.9Hz,2H),2.19–2.06(m,2H).MS(ESI)m/z:calculated forC23H19ClF3N5O5[M+H]+:528.10,found:528.88.。
实施例65
中间体5-氯-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)苯并呋喃-2-甲酰胺的合成
步骤1:5-氯-N-(哌啶-4-基)苯并呋喃-2-甲酰胺的合成
原料为实施例1步骤2所得的5-氯苯呋喃-2-羧酸、4-氨基哌啶-1-甲酸叔丁酯。参照实施例1步骤3的合成。后经1.5ml三氟乙酸脱Boc,得白色酯状固体2.3g,产率84.31%。1HNMR(300MHz,DMSO-d6)δ8.92(d,J=7.6Hz,1H),8.68(s,1H),7.89(d,J=2.2Hz,1H),7.71(d,J=8.8Hz,1H),7.58(d,J=1.0Hz,1H),7.49(dd,J=8.8,2.2Hz,1H),4.15(d,J=5.2Hz,1H),4.12–4.02(m,1H),3.32(s,1H),3.03(td,J=12.6,3.1Hz,2H),1.97(dd,J=13.8,3.9Hz,2H),1.86–1.72(m,2H).
步骤2:2-(4-(5-氯苯呋喃-2-甲酰胺)哌啶-1-基)-2-氧代乙酸乙酯的合成
参照实施例3步骤2所述方法,得白色固体1.74g,产率72.3%。1H NMR(400MHz,Chloroform-d)δ7.65(d,J=2.0Hz,1H),7.44(d,J=8.6Hz,2H),7.38(dd,J=8.8,2.1Hz,1H),6.69(d,J=8.1Hz,1H),4.54(ddt,J=13.5,4.5,2.6Hz,1H),4.35(q,J=7.1Hz,2H),4.28(ddt,J=11.7,8.2,4.0Hz,1H),3.75(ddt,J=13.8,5.1,2.8Hz,1H),3.28(ddd,J=14.1,11.9,2.8Hz,1H),2.93(ddd,J=13.5,12.0,3.0Hz,1H),2.27–2.09(m,2H),1.71–1.51(m,2H),1.37(t,J=7.1Hz,3H).
步骤3:5-氯-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)苯并呋喃-2-甲酰胺的合成
参照实施例3步骤1所述方法,于85℃反应。得白色固体543mg,产率60.17%。1HNMR(400MHz,DMSO-d6)δ9.77(s,1H),8.75(d,J=7.9Hz,1H),7.88(d,J=2.3Hz,1H),7.70(d,J=8.8Hz,1H),7.55(s,1H),7.49(dd,J=9.0,2.3Hz,1H),4.51(d,J=23.5Hz,1H),4.43(s,1H),4.27(d,J=13.3Hz,1H),4.17–4.02(m,1H),3.79(d,J=13.5Hz,1H),3.21–3.13(m,1H),2.90–2.78(m,1H),1.85(d,J=11.9Hz,2H),1.63–1.42(m,2H).。
实施例66
5-氯-N-(1-(5-((1s,3s)-3-(三氟甲氧基)环丁基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)苯并呋喃-2-甲酰胺(Ⅰ-29)的合成
步骤1:5-氯-N-(1-(2-氧代-2-(2-((1s,3s)-3-(三氟甲氧基)环丁烷-1-羰基)肼基)乙酰基)哌啶-4-基)苯并呋喃-2-甲酰胺的合成
原料为实施例65步骤3所得的5-氯-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)苯并呋喃-2-甲酰胺、实施例63步骤3所得(1s,3s)-3-(三氟甲氧基)环丁烷-1-甲酸。参照实施例1步骤3的合成,得白色固体203mg,产率54.89%。1H NMR(400MHz,DMSO-d6)δ10.05(s,1H),8.79(t,J=7.5Hz,2H),7.93–7.89(m,1H),7.70(s,1H),7.55–7.51(m,1H),7.48(d,J=2.3Hz,1H),4.82(p,J=7.6Hz,1H),4.31(d,J=14.7Hz,1H),4.12(dd,J=7.4,3.8Hz,1H),3.98(d,J=13.3Hz,1H),2.98–2.81(m,2H),2.72(tt,J=9.4,7.5Hz,1H),2.60–2.52(m,2H),2.36–2.19(m,2H),1.57(dddt,J=37.1,19.3,11.4,6.0Hz,4H).
步骤2:5-氯-N-(1-(5-((1s,3s)-3-(三氟甲氧基)环丁基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)苯并呋喃-2-甲酰胺的合成
参照实施例39中步骤3的合成得白色固体26.3mg,产率21.07%。1H NMR(400MHz,Chloroform-d)δ7.66(d,J=2.0Hz,1H),7.42(s,2H),7.38(dd,J=9.0,2.1Hz,1H),6.63(d,J=8.1Hz,1H),4.98(dq,J=14.1,3.3Hz,1H),4.80–4.68(m,2H),4.35(tdt,J=11.6,8.2,4.2Hz,1H),3.53–3.36(m,2H),3.16–3.02(m,1H),2.91(dddt,J=9.9,7.4,5.3,2.7Hz,2H),2.84–2.70(m,2H),2.32–2.17(m,2H),1.79–1.57(m,2H).MS(ESI)m/z:calculated forC22H20ClF3N4O5[M+H]+:513.87,found:513.81.。
实施例67
中间体5-氯-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)-1H-吲哚-2-甲酰胺的合成
步骤1:5-氯-N-(哌啶-4-基)-1H-吲哚-2-甲酰胺的合成
原料为5-氯-1H-吲哚-2-羧酸、4-氨基哌啶-1-甲酸叔丁酯。参照实施例65步骤1的合成,得白色固体1.56g。产率72.14%。1H NMR(400MHz,DMSO-d6)δ11.82(d,J=2.2Hz,1H),8.77(s,1H),8.59(d,J=7.6Hz,1H),7.71(d,J=2.0Hz,1H),7.44(d,J=8.7Hz,1H),7.23–7.16(m,2H),4.09(dtt,J=10.3,7.0,3.4Hz,1H),3.38–3.31(m,2H),3.12–2.97(m,2H),2.06–1.95(m,2H),1.82–1.66(m,2H).
步骤2:2-(4-(5-氯-1H-吲哚-2-甲酰胺)哌啶-1-基)-2-氧代乙酸乙酯的合成
参照实施例3步骤2所述方法,得白色固体1.23g,产率43.21%。1H NMR(400MHz,DMSO-d6)δ11.81(d,J=2.2Hz,1H),8.45(d,J=8.0Hz,1H),7.71(d,J=2.0Hz,1H),7.43(d,J=8.7Hz,1H),7.18(dd,J=8.7,2.1Hz,1H),7.14(dd,J=2.1,0.9Hz,1H),4.31(qd,J=7.1,1.4Hz,2H),4.27–4.20(m,1H),4.15(ddq,J=11.5,8.0,4.1,3.7Hz,1H),3.62–3.51(m,1H),3.33–3.23(m,1H),2.94(td,J=12.8,2.9Hz,1H),1.92(dd,J=13.2,3.9Hz,2H),1.60–1.38(m,2H),1.28(t,J=7.1Hz,3H).
步骤3:5-氯-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)-1H-吲哚-2-甲酰胺的合成
参照实施例65步骤3的合成,得白色固体431mg,产率46.98%。1H NMR(400MHz,DMSO-d6)δ11.85–11.75(m,1H),9.79(s,1H),8.46(d,J=7.6Hz,1H),7.70(d,J=2.1Hz,1H),7.43(d,J=8.7Hz,1H),7.18(dd,J=8.8,2.1Hz,1H),7.16(d,J=1.6Hz,1H),4.50(d,J=47.4Hz,2H),4.27(d,J=13.2Hz,1H),4.18–4.03(m,1H),3.78(d,J=13.9Hz,1H),3.19(ddd,J=14.1,11.9,2.7Hz,1H),2.87(td,J=12.7,2.9Hz,1H),1.97–1.81(m,2H),1.50(dqd,J=39.8,12.4,4.5Hz,2H).。
实施例68
5-氯-N-(1-(5-((1s,3s)-3-(三氟甲氧基)环丁基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)-1H-吲哚-2-甲酰胺(Ⅰ-30)的合成
步骤1:5-氯-N-(1-(2-氧代-2-(2-((1s,3s)-3-(三氟甲氧基)环丁烷-1-羰基)肼基)乙酰基)哌啶-4-基)-1H-吲哚-2-甲酰胺的合成
原料为实施例67步骤3所得的5-氯-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)-1H-吲哚-2-甲酰胺、实施例63步骤3所得(1s,3s)-3-(三氟甲氧基)环丁烷-1-甲酸。参照实施例1步骤3的合成,得白色固体925mg,产率41.11%。1H NMR(400MHz,DMSO-d6)δ11.80(d,J=2.1Hz,1H),10.58(s,1H),10.04(s,1H),8.45(d,J=7.8Hz,1H),7.71(d,J=2.0Hz,1H),7.43(d,J=8.7Hz,1H),7.18(dd,J=8.9,2.0Hz,2H),4.82(p,J=7.6Hz,1H),4.27(d,J=13.2Hz,1H),4.14(pt,J=7.2,3.6Hz,1H),3.98(d,J=13.4Hz,1H),3.31–3.20(m,1H),2.91(td,J=12.9,3.0Hz,1H),2.72(tt,J=9.4,7.5Hz,1H),2.60–2.51(m,2H),2.36–2.21(m,2H),1.91(dt,J=13.2,7.3Hz,2H),1.58(qd,J=12.1,4.2Hz,1H),1.46(qd,J=12.3,4.3Hz,1H).
步骤2:5-氯-N-(1-(5-((1s,3s)-3-(三氟甲氧基)环丁基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)-1H-吲哚-2-甲酰胺的合成(Ⅰ-30)
参照实施例66步骤2的合成,得白色固体57mg,产率58.67%。1H NMR(400MHz,DMSO-d6)δ8.45(d,J=7.8Hz,1H),7.71(d,J=2.0Hz,1H),7.43(d,J=8.7Hz,1H),7.18(dd,J=8.9,2.0Hz,2H),4.82(p,J=7.6Hz,1H),4.27(d,J=13.2Hz,1H),4.14(pt,J=7.2,3.6Hz,1H),3.98(d,J=13.4Hz,1H),3.31–3.20(m,1H),2.91(td,J=12.9,3.0Hz,1H),2.72(tt,J=9.4,7.5Hz,1H),2.60–2.51(m,2H),2.36–2.21(m,2H),1.91(dt,J=13.2,7.3Hz,2H),1.58(qd,J=12.1,4.2Hz,1H),1.46(qd,J=12.3,4.3Hz,1H).MS(ESI)m/z:calculatedfor C22H21ClF3N5O4[M+H]+:511.89,found:511.74.。
实施例69
中间体2-((1s,3s)-3-(三氟甲氧基)环丁氧基)乙酸的合成
步骤1:(1s,3s)-3-(苄氧基)环丁烷-1-醇的合成
参照实施例63步骤1的合成,得无色液体5.40g,产率91.37%。1H NMR(500MHz,Chloroform-d)δ7.42–7.34(m,2H),7.32–7.22(m,3H),4.60(t,J=1.0Hz,2H),3.99(d,J=4.9Hz,1H),3.88(s,1H),3.66(d,J=4.9Hz,1H),1.98–1.85(m,3H).
步骤2:2-(3-对-(苄氧基)环丁氧基)乙酸叔丁酯的合成
原料为实施例63步骤1所得3-顺-(苄氧基)环丁醇,2-氯乙酸叔丁酯。将3-顺-(苄氧基)环丁醇(1.30g,7.29mmol)、CsCO3(2.81g,14.59mmol)溶于DMF(10ml),10min后加入2-氯乙酸叔丁酯(1.10g,7.29mmol),隔夜反应。用乙酸乙酯萃取,无水硫酸钠干燥,过滤,滤液经减压浓缩,残留物通过硅胶柱层析纯化得到无色液体2.10g,产率98.47%。1H NMR(400MHz,Chloroform-d)δ7.38-7.27(m,5H),4.42(s,2H),3.89(s,2H),3.75-3.62(m,2H),2.65(m,1H),2.09-1.99(s,4H),1.47(s,9H).
步骤3:2-(3-顺-羟基环丁氧基)乙酸叔丁酯的合成
N2保护,Pd/C(230mg,10%Pd/C)加入到2-(3-对-(苄氧基)环丁氧基)乙酸叔丁酯(2g,684mmol)的MeOH(25ml)。H2下,于50℃下搅拌5h。将反应物经硅藻土过滤,滤液旋干得淡黄色液体1.27g,产率91.80%。1H NMR(400MHz,Chloroform-d)δ3.95-3.89(m,1H),3.89(s,2H),3.71-1.62(m,1H),2.77-2.67(m,2H),2.00-1.91(m,2H),1.80(s,1H),1.47(s,9H).
步骤4:2-(3-氯-(三氟甲氧基)环丁氧基)乙酸叔丁酯的合成
参照实施例63步骤2的合成,得无色液体1.01g,产率41.22%。1H NMR(300MHz,Chloroform-d)δ4.36-4.26(m,1H),3.89(s,2H),3.82-3.73(m,1H),2.86-2.70(m,2H),2.37-2.28(m,2H),1.47(s,9H).
步骤5:2-((1s,3s)-3-(三氟甲氧基)环丁氧基)乙酸的合成
将2-(3-氯-(三氟甲氧基)环丁氧基)乙酸叔丁酯(1.01g)用DCM(8ml)溶解,加入TFA 2ml,隔夜反应。将反应液浓缩,无需纯化直接用于下一步。得淡黄色液体800mg,产率100%。1NMR(400MHz,Chloroform-d):δ4.26-4.19(m,1H),4.00(s,2H),3.73-3.70(m,1H),2.77-2.74(m,2H),2.27-2.24(m,2H).。
实施例70
N-((1r,4R)-4-(5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)环己基)-2-(((1s,3S)-3-(三氟甲氧基)环丁氧基)乙酰胺(Ⅱ-18)的合成
原料为实施例40步骤2所得的(1r,4r)-4-(5-(5-氯苯并呋喃-2-基)-1,3,4-恶二唑-2-基)环己烷-1-胺、实施例69步骤5所得的2-((1s,3s)-3-(三氟甲氧基)环丁氧基)乙酸。参照实施例1步骤3的合成,得白色固体34mg,产率41.22%。1H NMR(300MHz,DMSO-d6)δ(ppm):8.07(d,J=8.2Hz,1H),7.90(s,1H),7.84(d,J=8.9Hz,1H),7.77(d,J=6.9Hz,1H),7.54(d,J=9.0Hz,1H),4.49(s,2H),4.26-4.19(m,1H),3.72(d,J=9.2Hz,1H),3.72-3.70(m,1H),3.11-2.93(m,3H),2.19(d,J=13.5Hz,2H),2.27-2.24(m,2H),1.91(d,J=12.3Hz,2H),1.67(d,J=12.4Hz,2H),1.47(q,J=12.6Hz,2H);MS(ESI)m/z:calculated forC23H23ClF3N3O5[M+H]+:514.90,found:514.56.。
实施例71
中间体6-溴-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)喹啉-3-甲酰胺的合成
步骤1:6-溴-N-(哌啶-4-基)喹啉-3-甲酰胺的合成
参照实施例65步骤1的合成,得黄白色固体1.02g。产率74.15%。1H NMR(300MHz,Chloroform-d)δ8.34(d,J=8.5Hz,1H),8.23(d,J=8.5Hz,1H),8.16(d,J=8.5Hz,1H),8.06(d,J=2.2Hz,1H),8.02(d,J=9.0Hz,1H),7.85(dd,J=9.0,2.2Hz,1H),4.16(dddd,J=15.1,10.9,8.4,4.1Hz,1H),3.23(dt,J=12.7,3.7Hz,2H),2.85(td,J=11.9,2.6Hz,2H),2.13(dd,J=13.1,3.7Hz,2H),1.75–1.54(m,2H).
步骤2:2-(4-(6-溴喹啉-3-甲酰胺)哌啶-1-基)-2-氧代乙酸乙酯的合成
参照实施例65步骤2的合成,得白色固体1.3g,产率87.88%。1H NMR(300MHz,Chloroform-d)δ8.33(d,J=8.5Hz,1H),8.29–8.23(m,1H),8.19(d,J=8.4Hz,1H),8.07(d,J=2.1Hz,1H),8.00(d,J=9.0Hz,1H),7.86(dd,J=9.0,2.2Hz,1H),4.56(dd,J=11.6,6.9Hz,1H),4.43–4.25(m,3H),3.86–3.70(m,1H),3.32(ddd,J=14.2,11.8,2.8Hz,1H),3.00(ddd,J=13.6,11.8,3.0Hz,1H),2.30–2.13(m,2H),1.71(pd,J=11.9,4.3Hz,2H),1.40(t,J=7.1Hz,3H).
步骤3:6-溴-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)喹啉-3-甲酰胺的合成
参照实施例65步骤3的合成,得白色固体534mg,产率78.06%。1H NMR(400MHz,DMSO-d6)δ9.43(d,J=274.5Hz,1H),8.86(d,J=8.4Hz,1H),8.54(d,J=8.6Hz,1H),8.41(d,J=2.2Hz,1H),8.19(d,J=8.5Hz,1H),8.09(d,J=9.0Hz,1H),7.99(dd,J=9.0,2.2Hz,1H),4.62–4.38(m,2H),4.30(d,J=13.2Hz,1H),4.15(dddd,J=15.8,10.5,8.0,4.7Hz,1H),3.82(d,J=13.6Hz,1H),3.27–3.13(m,1H),2.86(td,J=13.0,3.1Hz,1H),1.90(ddd,J=12.3,8.1,3.9Hz,2H),1.65(dqd,J=28.6,12.3,4.2Hz,2H).。
实施例72
6-溴-N-(1-(5-((1s,3s)-3-(三氟甲氧基)环丁基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)喹啉-3-甲酰胺(Ⅰ-31)的合成
步骤1:6-溴-N-(1-(2-氧代-2-(2-((1s,3s)-3-(三氟甲氧基)环丁烷-1-羰基)肼基)乙酰基)哌啶-4-基)喹啉-3-甲酰胺的合成
参照实施例66步骤1的合成,得白色固体347mg,产率53.25%。1H NMR(400MHz,DMSO-d6)δ10.42(d,J=105.6Hz,1H),10.05(s,1H),8.85(d,J=8.3Hz,1H),8.55(d,J=8.5Hz,1H),8.41(d,J=2.2Hz,1H),8.19(d,J=8.5Hz,1H),8.09(d,J=9.0Hz,1H),7.99(dd,J=9.0,2.3Hz,1H),4.82(p,J=7.6Hz,1H),4.30(d,J=13.2Hz,1H),4.25–4.09(m,1H),4.02(t,J=10.6Hz,1H),3.27(t,J=12.5Hz,1H),2.90(t,J=12.3Hz,1H),2.72(tt,J=9.2,7.4Hz,1H),2.60–2.51(m,2H),2.38–2.19(m,2H),1.92(d,J=7.4Hz,2H),1.68(dqd,J=41.3,12.2,4.2Hz,2H).
步骤2:6-溴-N-(1-(5-((1s,3s)-3-(三氟甲氧基)环丁基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)喹啉-3-甲酰胺的合成
参照实施例66步骤2的合成,得白色固体40mg,产率22.51%。1H NMR(400MHz,Chloroform-d)δ8.32(d,J=8.4Hz,1H),8.23(d,J=8.6Hz,1H),8.20(d,J=8.2Hz,1H),8.05(s,1H),7.97(d,J=8.9Hz,1H),7.84(d,J=9.1Hz,1H),5.08–4.90(m,1H),4.74(p,J=7.0,6.1Hz,2H),4.37(ddp,J=11.8,8.5,4.2Hz,1H),3.63–3.35(m,2H),3.25–3.05(m,1H),3.02–2.86(m,2H),2.78(q,J=10.2Hz,2H),2.26(dt,J=12.9,4.0Hz,2H),1.77(dqd,J=24.6,12.0,4.2Hz,2H).MS(ESI)m/z:calculated for C23H21BrF3N5O4[M+H]+:569.35,found:569.21.。
实施例73
中间体2-(三氟甲氧基)乙烷-1-醇的合成
步骤1:(2-(三氟甲氧基)乙氧基)甲基)苯的合成
原料为2-苄氧基乙醇。参照实施例63步骤2的合成得无色液体1.37g,产率45.76%。1HNMR(300MHz,Chloroform-d)δ7.31(s,5H),4.60(s,2H),4.16-4.10(m,2H),3.74-3.67(m,2H).
步骤2:2-(三氟甲氧基)乙烷-1-醇的合成
参照实施例69步骤3的无色液体782mg,产率:96.63%。1H NMR(300MHz,Chloroform-d)δ4.16-4.10(m,2H),3.74(t,J=4.5Hz,2H).。
实施例74
6-溴-N-(1-(5-(2-(三氟甲氧基)乙氧基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)喹啉-3-甲酰胺(Ⅰ-32)的合成
步骤1:2-(三氟甲氧基)乙基-2-(2-(4-(6-溴喹啉-3-甲酰胺)哌啶-1-基)-2-氧代乙酰基)肼-1-羧酸酯得合成
在0℃下,将吡啶(134mg,1.69mmol)投入2-(三氟甲氧基)乙烷-1-醇(146mg,1.13mmol)和三光气(67mg,225.48μmol)的THF(3ml)中,搅拌60min后投入6-溴-N-(1-(2-肼基-2-氧代乙酰基)哌啶-4-基)喹啉-3-甲酰胺(327mg,567.39μmol),室温隔夜反应。将反应液用EA/H2O萃取,收集EA相。EA相用Na2SO4干燥,抽滤,滤液浓缩,残留物通过硅胶柱层析纯化得白色固体134mg,产率46.53%。1H NMR(400MHz,DMSO-d6)δ10.42(d,J=105.6Hz,1H),10.05(s,1H),8.85(d,J=8.3Hz,1H),8.55(d,J=8.5Hz,1H),8.41(d,J=2.2Hz,1H),8.19(d,J=8.5Hz,1H),8.09(d,J=9.0Hz,1H),7.99(dd,J=9.0,2.3Hz,1H),4.30(d,J=13.2Hz,1H),4.25-4.09(m,3H),4.02(t,J=10.6Hz,1H),4.00-3.96(m,2H),3.27(t,J=12.5Hz,1H),2.90(t,J=12.3Hz,1H),1.92(d,J=7.4Hz,2H),1.68(dqd,J=41.3,12.2,4.2Hz,2H).
步骤2:6-溴-N-(1-(5-(2-(三氟甲氧基)乙氧基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)喹啉-3-甲酰胺的合成
参照实施例66步骤2的合成,得白色固体27mg,产率32.11%。1H NMR(300MHz,Chloroform-d)δ8.33(d,J=8.5Hz,1H),8.29–8.23(m,1H),8.19(d,J=8.4Hz,1H),8.07(d,J=2.1Hz,1H),8.00(d,J=9.0Hz,1H),7.86(dd,J=9.0,2.2Hz,1H),4.40(s,2H),4.56(dd,J=11.6,6.9Hz,1H),4.43–4.25(m,3H),3.98(d,J=12.3Hz,1H),3.86–3.70(m,1H),3.82(d,J=12.5Hz,1H),3.32(ddd,J=14.2,11.8,2.8Hz,1H),3.00(ddd,J=13.6,11.8,3.0Hz,1H),2.30–2.13(m,2H),1.71(pd,J=11.9,4.3Hz,2H),1.40(t,J=7.1Hz,3H).MS(ESI)m/z:calculated for C21H19BrF3N5O5[M+H]+:558.31,found:558.75.。
实施例75
5-氯-N-(1-(5-(2-(三氟甲氧基)乙氧基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)苯并呋喃-2-甲酰胺(Ⅰ-33)的合成
/>
步骤1:2-(三氟甲氧基)乙基-2-(2-(4-(5-氯苯并呋喃-2-甲酰胺)哌啶-1-基)-2-氧代乙酰基)肼-1-羧酸盐的合成
参照实施例74步骤1的合成,得白色固体178mg,产率:50.83%。1H NMR(300MHz,DMSO-d6)δ11.27(s,1H),9.49(s,1H),8.92(d,J=7.6Hz,1H),7.89(d,J=2.2Hz,1H),7.71(d,J=8.8Hz,1H),7.58(d,J=1.0Hz,1H),7.49(dd,J=8.8,2.2Hz,1H),4.23(s,2H),4.15(d,J=5.2Hz,1H),4.12–4.02(m,3H),3.32(s,1H),3.03(td,J=12.6,3.1Hz,2H),1.97(dd,J=13.8,3.9Hz,2H),1.86–1.72(m,2H).
步骤2:5-氯-N-(1-(5-(2-(三氟甲氧基)乙氧基)-1,3,4-恶二唑-2-羰基)哌啶-4-基)苯并呋喃-2-甲酰胺的合成
参照实施例66步骤2的合成,得白色固体19mg,产率22.36%。1H NMR(400MHz,Chloroform-d)δ7.66(d,J=2.0Hz,1H),7.42(s,2H),7.38(dd,J=9.0,2.1Hz,1H),6.63(d,J=8.1Hz,1H),4.98(dq,J=14.1,3.3Hz,1H),4.80–4.68(m,1H),4.40-4.35(m,3H),4.02–3.81(m,2H),3.53–3.36(m,2H),2.32–2.17(m,2H),1.79–1.57(m,2H).MS(ESI)m/z:calculated for C20H18ClF3N4O6[M+H]+:503.83,found:503.09.。
实施例76
5-氯-N-(1-(3-(4-氯苯基)-1,2,4-恶二唑-5-羰基)哌啶-4-基)-1H-吲哚-2-甲酰胺(Ⅰ-34)的合成
原料为实施例11步骤3所得的3-(4-氯苯基)-1,2,4-恶二唑-5-羧酸、实施例67步骤1所得的5-氯-N-(哌啶-4-基)-1H-吲哚-2-甲酰胺。参照实施例66步骤1的合成,得白色固体47mg,产率54.71%。1H NMR(400MHz,DMSO-d6)δ11.79(d,J=2.1Hz,1H),8.46(d,J=7.8Hz,1H),8.19–7.98(m,2H),7.70(d,J=2.1Hz,2H),7.68(d,J=2.0Hz,1H),7.43(dt,J=8.8,0.7Hz,1H),7.22–7.06(m,2H),5.75(s,1H),4.46(d,J=13.3Hz,1H),4.27–4.16(m,1H),3.43(td,J=13.9,12.9,2.8Hz,1H),3.26–3.06(m,2H),2.04(s,1H),1.92(d,J=12.7Hz,1H),1.63(tdd,J=23.9,12.1,4.3Hz,2H).MS(ESI)m/z:calculated forC23H19Cl2N5O3[M+H]+:485.34,found:485.08.。
试验例1
ATF4抑制率和IC50的测定
将处于对数生长期的HEK-293T细胞接种于12孔板,贴壁培养12h,加入待测化合物(500nM)作用1h后,再给予毒胡萝卜素(Tg,100nM),共同孵育3h。弃去原培养基,用PBS缓冲溶液洗涤3次,于冰上加入细胞裂解液,收取蛋白样品,用于SDS-PAGE电泳。后转移到NC膜。室温封闭1h后,ATF4一抗溶液(1:1000)4℃孵育过夜。TBST溶液洗涤3次,HRP标记的二抗溶液室温孵育1h。TBST溶液洗涤3遍后,化学发光器曝光。条带灰度值用Image J软件进行分析。
表1化合物对HEK-293T细胞ATF4抑制率和部分IC50值
由表可以看出本发明中的化合物对于HEK-293T细胞ATF4表达抑制明显。相对于先导化合物ISRIB,化合物Ⅰ-13、Ⅰ-14、Ⅰ-18、Ⅰ-19、Ⅱ-2和Ⅱ-4抑制率活性略优或大致相当。相对于先导化合物ISRIB,化合物Ⅰ-14、Ⅰ-18和Ⅱ-2的ATF4 IC50具有较好的数值,显示很好的活性。说明化合物具有激活eIF2B,逆转ISR引起的神经损伤,治疗神经退行性疾病的能力。
试验例2
SDS-PAGE法测蛋白翻译率
将处于对数生长期的CHO细胞接种于6孔板,贴壁培养12h,弃去原培养基,PBS溶液洗涤细胞一次,加入含待测化合物(500nM)的无血清培养基作用1h后,再给予毒胡萝卜素(Tg,100nM)共同孵育24h。在处理24h后,收集细胞上清,并加入PMSF,在2000×g,4℃的条件下离心10min去除细胞碎片;并加入400μL的甲醇,剧烈混匀,并加入200μL的氯仿,剧烈混匀并涡旋,在4℃14000×g离心10min,丢弃上清液;沉淀加入400μL的甲醇混匀,4℃17000×g10min,弃去上清液,沉淀晾干,加入上样缓冲液,即为上清中蛋白质样品,进行SDS-PAGE电泳,考马斯亮蓝染色,再用脱色液洗至背景干净,用化学发光器曝光。
表2化合物对CHO细胞蛋白质翻译影响测定
/>
由表可以看出本发明中的化合物对于CHO细胞蛋白质翻译具有较好的促进作用。相对于先导化合物ISRIB,化合物Ⅰ-2、Ⅰ-9、Ⅰ-10、Ⅰ-11、Ⅰ-15、Ⅰ-16、Ⅰ-17、Ⅰ-25、Ⅰ-26、Ⅰ-28和Ⅱ-5能更好的蛋白质翻译恢复率,并且能接近或超过空白组的数值,说明化合物能通过激活eIF2B明显促进蛋白质合成的恢复,可以逆转ISR引起的神经损伤,治疗神经退行性疾病。
Claims (8)
1.具有式(I)或式(II)结构的化合物,其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物,
其中:
A为卤素取代的双芳香杂环;
D选自
L为
W为五元杂环;
n为0、1或2;
m为0或1;
B为卤素取代的苯环、
K选自
G选自
2.根据权利要求1所述的具有式(I)或式(II)结构的化合物,其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物,其特征在于:
A选自
3.根据权利要求1所述的具有式(I)或式(II)结构的化合物,其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物,其特征在于:
W选自
4.根据权利要求1所述的具有式(I)或式(II)结构的化合物,其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物,其特征在于:
B选自
5.选自以下的化合物,其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物,
6.一种药物组合物,以权利要求1-5任一项所述化合物、其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物为活性成分或者主要活性成分,辅以药学上可接受的载体组成。
7.权利要求1-5任一项所述化合物、其立体异构体、其几何异构体、其互变异构体、其药学上可接受的盐、其前药、其水合物或其溶剂化物在制备治疗和/或预防神经退行性疾病的药物中的应用。
8.根据权利要求7所述的应用,其特征在于:所述神经退行性疾病为阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩性侧索硬化、衰老、孤独症谱系障碍、白质消融性疾病、痴呆或额颞叶型痴呆。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2023/096760 WO2023231948A1 (zh) | 2022-05-30 | 2023-05-29 | Isr抑制剂及其制备方法和应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210601585 | 2022-05-30 | ||
CN2022106015857 | 2022-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116768877A true CN116768877A (zh) | 2023-09-19 |
Family
ID=87995505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310592077.1A Pending CN116768877A (zh) | 2022-05-30 | 2023-05-24 | Isr抑制剂及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116768877A (zh) |
WO (1) | WO2023231948A1 (zh) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1907384A2 (en) * | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
GB0813740D0 (en) * | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
MA50063A (fr) * | 2017-09-01 | 2021-04-28 | Denali Therapeutics Inc | Composés, compositions et procédés |
CN112218851A (zh) * | 2017-11-02 | 2021-01-12 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
AR118837A1 (es) * | 2019-04-30 | 2021-11-03 | Calico Life Sciences Llc | Moduladores de la vía integrada del estrés |
EP3962899A1 (en) * | 2019-04-30 | 2022-03-09 | Calico Life Sciences LLC | Substituted cyclolakyls as modulators of the integrated stress pathway |
IL302440A (en) * | 2020-10-30 | 2023-06-01 | Calico Life Sciences Llc | Combined pressure pathway modulators |
US20230083885A1 (en) * | 2021-04-02 | 2023-03-16 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
-
2023
- 2023-05-24 CN CN202310592077.1A patent/CN116768877A/zh active Pending
- 2023-05-29 WO PCT/CN2023/096760 patent/WO2023231948A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023231948A1 (zh) | 2023-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3328843B1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
JP6422438B2 (ja) | RORγT阻害剤としての4−ヘテロアリール置換安息香酸化合物およびその使用 | |
EP3743430B1 (en) | Aminopyrrolotriazines as kinase inhibitors | |
WO2006088246A1 (ja) | Gpr34受容体機能調節剤 | |
US11976062B2 (en) | Benzisoxazole compound | |
EP3704118B1 (en) | Aminoimidazopyridazines as kinase inhibitors | |
WO2014074675A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
KR20050044407A (ko) | N,n'-치환-1,3-디아미노-2-히드록시프로판 유도체 | |
JP5451633B2 (ja) | トリアゾールオキサジアゾール誘導体 | |
CN109415358B (zh) | 作为RORγt调节剂的6-氨基吡啶-3-基噻唑 | |
TWI794880B (zh) | 作為組蛋白去乙醯酶6抑制劑之新穎化合物及包含其之醫藥組合物 | |
JP7301171B2 (ja) | ヒストン脱アセチル化酵素6阻害剤としての1,3,4-オキサジアゾール誘導体化合物、およびそれを含む薬剤学的組成物 | |
EP3849968B1 (en) | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) | |
CN106795152B (zh) | 蛋白激酶抑制剂 | |
TW201702226A (zh) | 尿素衍生物或其醫藥上可接受鹽 | |
JP7428833B2 (ja) | ヒストン脱アセチル化酵素6阻害剤としての1,3,4-オキサジアゾール誘導体化合物、およびそれを含む医薬組成物 | |
TW202233620A (zh) | Cftr調節劑化合物、組合物及其用途 | |
EP3619200B1 (en) | Heterocyclic p2x7 antagonists | |
CN113321640B (zh) | 一种吲哚类化合物及其应用 | |
CN116768877A (zh) | Isr抑制剂及其制备方法和应用 | |
CA2653524A1 (en) | Pyrrolidine derivatives useful against diseases that depends on activity of renin | |
AU2022356017B2 (en) | Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | |
CN117865966A (zh) | 氨基甲酸酯类化合物及其制备方法和医药用途 | |
CN117881675A (zh) | 2,4-二氢-3h-1,2,4-三唑-3-酮p2x7拮抗剂 | |
TW202115023A (zh) | 新型細胞凋亡訊號調節激酶1抑制劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |